



**Academic Appointments (continued):**

1994 – 1998, Assistant Professor of Urology and Medical Informatics, Scott Department of Urology and the Information Technology Program, Baylor College of Medicine, Houston, Texas

**Scientific Societies:**

American Statistical Association	1989–Present
The Institute of Management Sciences (TIMS/INFORMS)	1989–1997
Decision Sciences Institute	1989–1997
American Medical Informatics Association	1993–Present
Society for Medical Decision Making	1993–Present
Electronic Discussion List Moderator	1996–2003
19 <sup>th</sup> Annual Meeting Scientific Review Committee Chairman	1997
Officer Nominations Committee Member	1998
Annual Meeting Short Course Instructor	
“Machine Learning: Applying Artificial Neural Networks, Genetic Algorithms, and Recursive Partitioning to Health Care Data”	1997
“New Developments in the Use of Computers for Medical Decision Making”	1997
“Introduction to Survival Analysis and Prognostic Predictors”	2000–2001
American Urological Association, Affiliate Member	1996–2007
American Society of Clinical Oncology	2000–2007
American Association for Cancer Research	2002–2007

**Honors and Awards:**

Institute of Food Technologists National Scholarship	1986–1987
International Conference on Information Systems Doctoral Consortium	1992
Melcher College of Business Administration Award for Outstanding Teaching by a Doctoral Candidate	1992
Melcher College of Business Administration Dean’s Distinguished Dissertation Award	1993
First Prize in the Montague Boyd Essay Contest at the Southeastern Section of the AUA	1998
Second Prize in the Category of Clinical Research, 7 <sup>th</sup> Annual Methodist Hospital Oncology Research Seminar	1999
The Eugene L. Saenger Award for Distinguished Service to Society of Medical Decision Making (SMDM)	2008

**Grant Support (as Principal Investigator or Currently Funded Only):**

“A Comparative Effectiveness Comprehensive Risk Calculator for Dutasteride.”  
Principal Investigator, 2010-2011, GlaxoSmithKline LLC, \$58,337.

“Refinement and Enhancement of a Web-Based Risk Calculator Deployment System.”  
Principal Investigator, 2010-2013, NIH/National Library of Medicine, 1RC4LM010959-01, \$1,212,874.

“Exploring the Utility of a Robust Electronic Health Record System in Determining Comparative Benefit/Risk Outcomes from Therapy.” Principal Investigator, 2008-2009, AstraZeneca, \$779,900.

“Translational Methodologies.” Co-Director, 2007-2012, National Institutes Health, UL1 RR 024989-01, Clinical and Translational Science Award Working Group, \$79,555 annual direct costs.

**Grant Support (as Principal Investigator or Currently Funded Only) continued:**

“Using an EHR-based Clinical Data Repository to Determine Prescribing Patterns and Outcomes.”  
Principal Investigator, 2006-2009, AstraZeneca, \$1,153,200.00.

“Studies for Eradication of Brain Metastasis from Breast Cancer.” Co-Investigator, 2006 – 2011  
Department of Defense / Center for Excellence, \$1,748,985.

“Improving Colorectal Cancer Staging with Nomograms.” Co-Investigator, 2006-2007  
American Joint Committee on Cancer, \$27,016.

“Prediction Models for Patients with Chronic Kidney Disease who are Starting CERA Immediately.”  
Principal Investigator, 2006-2007, Roche Laboratories, Inc., \$27,700.

“Validation of Clinician’s Survival System.” Principal Investigator, 2006, NCI Contract. \$44,781.

“Natural History of Prostate Cancer, Prognostic Models, and Decision Making.” Principal Investigator,  
2001-2004, NIH/NCI, CA92629, SPORE Research Project, \$891,763.

“Informatics.” Principal Investigator, 2001-2004, NIH/NCI, CA92629, SPORE Core Facility, \$553,144.

“Prediction Methods for Prostate Cancer Progression.” Principal Investigator, 2000-2004  
American Cancer Society, RPG-00-202-01-CCE, \$434,342.

“The Use of Nomograms to Reduce Sample Sizes Necessary for Evaluation of Clinical Markers in  
Prostate Cancer.” Principal Investigator, 2000-2001, CapCURE, \$50,000.

“Imaging in Risk Assessment of Prostate Cancer Patients.” Co-Investigator, 1999-2004, NIH, \$992,450.

“Treatment Decision Intervention for Veterans with Prostate Cancer.” Co-Investigator, 1999-2001,  
Department of Veterans Affairs, \$386,622.

“A Comparison of NASA Induction Tools for the Creation of Decision Rules Regarding Treatment for  
Clinically Localized Prostate Cancer.” Principal Investigator, 1996-1997, NASA, \$55,000.

“Medical Informatics.” Principal Investigator, 1994-1998, NIH/NCI, SPORE Core, CA58204-03-CF3,  
\$70,000/year.

“Three Dimensional Reconstruction of the Prostate.” Principal Investigator, 1994-1995, NIH/NCI,  
SPORE Pilot Project, CA58204, \$30,000.

**Patents Awarded:**

“A Nomogram to Aid in the Decision to Treat Clinically Localized Prostate Cancer.” 1999, US Patent  
No: 5,993,388.

"Nomograms to Aid in the Treatment of Prostatic Cancer." 2002, US Patent No: 6,409,664.

**Patents Published:**

- “Method to determine outcome for patients with prostatic disease.” 2003, US Patent Publication Number: 20030235816
- “Methods to predict death from breast cancer.” 2005, US Patent Publication Number: 20050019798
- “Methods to predict additional nodal metastases in breast cancer patients.” 2005, US Patent Publication Number: 20050282146
- “Method to predict prostate cancer.” 2005, US Patent Publication Number: 20050282199
- “Method to predict positive repeat prostate biopsy.” 2007, US Patent Publication Number: 20070111269
- “Method to predict risk of BPH progression.” 2007, US Patent Publication Number: 20070134725

**Software:**

Various prognostic models (nomograms). Obtain from <http://www.nomograms.org>.

**Other Activities:**

**Invited Lectures:**

1. “A Comparison of Machine Learning Techniques.” Department of Family Medicine Seminar, Baylor College of Medicine, Houston, Texas, 1994.
2. “Machine Learning Models in Medical Outcomes Research.” Visiting Professor, Urology Grand Rounds, Baylor College of Medicine, Houston, Texas, 1994.
3. “The Role of Statistics in the Peer-Review Process.” American Urological Association Peer Review Seminar, Houston, Texas, 1994.
4. “A Decision Analysis Model for Treating Clinically Localized Prostate Cancer.” Research Conference, Section of General Internal Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 1995.
5. “A Model of Machine Learning Technique Performance.” Texas Women’s University, Houston, Texas, 1995.
6. “Should a SPOR Computer Network be Structured as an Interconnected or Isolated System, with a Web Page or Database Interface, as Read-Only or Interactive?” First National Cancer Institute Inter-SPOR Networking Meeting, Bethesda, Maryland, 1996.
7. “Statistics in the Peer-Review Process.” American Urological Association Peer-Review Seminar, Dallas, Texas, 1997.
8. “Recent Developments in Predicting Prognosis with Prostate Cancer.” US TOO Cancer Support Group, Houston, Texas, 1997.
9. “The Use of and Misuse of Nomograms for Clinically Localized Prostate Cancer.” Radiation Oncology Grand Rounds, Baylor College of Medicine, Houston, Texas, February 5, 1998.
10. “Cost Effectiveness of Interferon Therapy in Chronic Myelogenous Leukemia.” Visiting Faculty: Interferons Update Meeting, Annenberg Center for Health Sciences, Rancho Mirage, California, April 19-22, 1998.
11. “Are We Closer to Rational Selection?” Invited Discussant: 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, California, May 19, 1998.
12. “A Comparison of Techniques to Predict Individual Prognosis – Examples in Prostate Cancer.” Working Group on Individual Risk Assessment and Breast Cancer. European Institute of Oncology, Milan, Italy, October 28-29, 1999.
13. “Men and Cancer: Emerging Issues.” Memorial Sloan-Kettering Cancer Center, CancerSmart Lecture Series, November 18, 1999.

14. "The Importance of Using a Nomogram when Counseling the Patient with Clinically Localized Prostate Cancer: A Radiation Therapy Example." Health Policy Lecture Series, Northwestern University, December 16, 1999.
15. "Prognostic Nomograms for Clinically Localized Prostate Cancer." Department of Urology, University of Hamburg, Germany, March 1, 2000.
16. "Decision Analyses for the Treatment of Clinically Localized Prostate Cancer." Department of Urology, University of Hamburg, Germany, March 2, 2000.
17. "Treatment Decision Making for Patients with Clinically Localized Prostate Cancer." Research Methodology Conference, Department of General Internal Medicine, Cornell University, March 10, 2000.
18. "Outcomes Research in Prostate Cancer." Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, April 13, 2000.
19. "Prostate-Specific Antigen: Screening and Prognosis for Primary and Recurrent Disease." 36<sup>th</sup> American Society of Clinical Oncology Annual Meeting, New Orleans, Louisiana, May 20-21, 2000.
20. "Outcomes Analysis." The Princess Margaret Hospital, Toronto, Canada, September 18, 2000.
21. "How to Select Treatment for Prostate Cancer." The Princess Margaret Hospital, Toronto, Canada, September 18, 2000.
22. "The Use Of Nomograms To Reduce Sample Sizes Necessary For Evaluation Of Clinical Markers In Prostate Cancer." 7th Annual CaPCURE Conference, Reno, Nevada, September 23, 2000.
23. "Can We Predict Outcomes?" 10<sup>th</sup> Annual Issues and Controversies in Prostate Cancer, Chateau Whistler, B.C., Canada, March 18, 2001.
24. "Role of Nomograms in Clinically Localized Prostate Cancer." Department of Urology, University of Texas M. D. Anderson Cancer Center, April 3, 2001.
25. "Prostate Cancer Nomograms: Devices Which Predict Treatment Outcomes." 43<sup>rd</sup> Science Writers Seminar of the American Cancer Society, Dana Point, California, April 25, 2001.
26. "Using Modern Medical Informatics and the Tools of Artificial Intelligence to Develop Risk Profiles." MSKCC Course in: Clinical Research and Outcomes Analysis, April 30, 2001.
27. "Can We Predict Outcomes?" Issues and Controversies in Prostate Care, Ontario Regional Meeting, Scottsdale, Arizona, May 19, 2001.
28. "Statistical Models Predicting Relapse After Local Treatments." 1<sup>st</sup> International Prostate Cancer Conference, San Juan, Puerto Rico, June 27, 2001.
29. "Decision Making Tables, Which Are Best, And How Accurate Are They?" British Columbia Regional International Conference on Prostate Cancer Meeting, Quadra Island, B.C., Canada, August 18, 2001.
30. "Prostate Cancer Nomograms: A Tool for Decision Making." US TOO! Prostate Cancer Survivors Support Group, Memorial Sloan-Kettering Cancer Center, New York, October 18, 2001.
31. "Nomograms for Predicting Outcomes." Informatics Solutions for Prostate Cancer, Toronto, October 27, 2001.
32. "Nomograms in the Management of Prostate Cancer." Thomas Jefferson University 12th Annual Urology Update Symposium, Philadelphia, November 1, 2001.
33. "Prostate Cancer Nomograms: A Tool for Decision Making." MAN to MAN Prostate Cancer Survivors Support Group, American Cancer Society, New York, November 13, 2001.
34. "Predicting Clinical Outcome in Prostate Cancer: Nomograms and Other Strategies." Department of Urology Grand Rounds, Columbia University, New York, January 31, 2002.
35. "How To Know When You Should Use A Prognostic Model." CaPSURE 2002 Investigators Meeting, San Diego, California, March 9, 2002.
36. "Predictors of Disease Progression in Prostate Cancer." 1<sup>st</sup> Annual Opinion Leader Summit, Barcelona, April 18, 2002.
37. "Approaches Toward Outcomes Analysis." 23<sup>rd</sup> American Brachytherapy Society Meeting, Orlando Florida, May 24, 2002.

38. "Algorithms for Prostate Cancer: From Diagnosis to Outcomes." 2<sup>nd</sup> International Prostate Cancer Congress, St. Thomas, U.S.V.I., July 19, 2002.
39. "Predictive Models of Prostate Cancer Progression." Prostate 2002 International Conference, Molecular Mechanisms as Targets in Prostatic Diseases, Liverpool, England, September 19, 2002.
40. "Prostate Cancer Nomograms." Dana-Farber Cancer Institute's Genitourinary Oncology Seminar Series, Boston, Massachusetts, October 2, 2002.
41. "Nomograms and Prediction Models in Prostate and Other Cancers." Population Science Conference, Fox Chase Cancer Center, Philadelphia, November 12, 2002.
42. "Predicting Outcomes: Innovative Use of Neural Networks and Nomograms." Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment, Cambridge, Massachusetts, November 15, 2002.
43. "Nomograms as Counseling Tools." Society for Urologic Oncology Annual Meeting, Bethesda, Maryland, December 13, 2002.
44. "Should We Predict Health Outcomes The Way We Predict Financial Outcomes?" American Statistical Association, New York, New York, December 17, 2002.
45. "Nomograms for Cancer Prediction" MD Anderson, Department of Biostatistics, Houston, Texas, February 5, 2003.
46. "Modeling Patient Prognosis." MD Anderson 10<sup>th</sup> Annual Genitourinary Oncology Conference, Houston, Texas, February 6, 2003.
47. "Risk Assessment in Prostate Cancer." NCCN 8<sup>th</sup> Annual Conference. Hollywood, Florida, Friday, March 15, 2003.
48. "The Predictive Value of Nomograms Used in Conjunction with Surgery/Hormonal Therapy." Takeda European Medical Congress for Urology. Budapest, Hungary, March 29, 2003.
49. "The Predictive Value of Nomograms Used in Conjunction with Brachytherapy and Radiotherapy." Takeda European Medical Congress for Urology. Budapest, Hungary, March 30, 2003.
50. "Predicting Risk with the Use of Nomograms." Charles Huggins Symposium. Chicago, IL, April 25, 2003.
51. "Predicting Patient Outcomes with Nomograms." Indiana University-Purdue University Indianapolis Cancer Center Grand Rounds, Indianapolis, IN, May 16, 2003.
52. "Predicting Patient Outcomes with Nomograms." Urology Grand Rounds, Montefiore Hospital, Bronx, New York, June 30, 2003.
53. "Nomograms in Prostate Cancer." Third International Prostate Cancer Congress. Southampton, Bermuda, July 17, 2003.
54. "Nomograms for Urologic Malignancies." National Medical Association, Annual Meeting, Philadelphia, PA, August 4, 2003.
55. "Predicting Patient Outcomes with Nomograms." Swedish Hospital, Seattle, WA, October 16, 2003.
56. "Prediction Models at the Bedside." Fred Hutchinson Cancer Research Center, Seattle, WA, October 16, 2003.
57. "The Predictive Value of Nomograms Used in Conjunction with Surgery/Hormonal Therapy." Takeda European Medical Congress, Prague, Czech Republic, October 25, 2003.
58. "The Predictive Value of Nomograms Used in Conjunction with Brachytherapy and Radiotherapy." Takeda European Medical Congress, Prague, Czech Republic, October 26, 2003.
59. "Clinical Prognostic Factors." 3<sup>rd</sup> International Symposium on Genitourinary Cancers, Santa Barbara, February 28, 2004.
60. "Integrating Risk Into Early Detection." Chemoprevention of Prostate Cancer, Reston, Virginia, March 5, 2004.
61. "Use of Nomograms to Predict Individual Cancer Patient Risk." The Society of Surgical Oncology Cancer Symposium, New York, March 18, 2004.
62. "Risk Stratification and Risk Assessment Tools." Leuprorelin European Medical Congress, Lisbon, Portugal, April 3, 2004.

63. "Comparing the Accuracy of Prediction Models." Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application, Washington, D. C., May 21, 2004.
64. "Measuring QOL After Surgery." 4<sup>th</sup> International Prostate Cancer Congress, Grand Bahama Island, Bahamas, July 16, 2004.
65. "Cancer Prediction Models." Intelligent Data Analysis in Medicine and Pharmacology 2004 Workshop, Palo Alto, September 6, 2004.
66. "Risk: Stratification and Risk Assessment Tools." Takeda European Medical Congress in Urology, Warsaw Poland, October 9, 2004.
67. "Understanding and Defining Risk." 1<sup>st</sup> Annual New Perspectives on Prostate Cancer Symposium, Roslyn, New York, November 11, 2004.
68. "Nomograms and their Integration into the Clinic." 1<sup>st</sup> Annual New Perspectives on Prostate Cancer Symposium, Roslyn, New York, November 11, 2004.
69. "Predictive Medicine in Prostate Cancer Management" Sistema Congressi, Abano Terme, Italy, November 19, 2004.
70. "This House Believes that the Application of Risk Assessment Tools in Clinical Practice is Limited--Against." Takeda European Medical Congress in Urology, Barcelona, Spain, April 8-10, 2005.
71. "Medical Prediction Models." Beckman Coulter Science and Technology 2005 Symposium, Fullerton, California, August 24, 2005.
72. "Nomograms and Prostate Cancer Prediction." 1<sup>st</sup> International Conference on Urogenital Disorders – from Gene to Clinics, Malmö, Sweden, September 1-3, 2005.
73. "Significant and non-Significant Prostate Cancer" and "Decision Making for Prostate Cancer: the Risk of Undertreatment and Overtreatment." PSA: Past, Present and Future, Istituto Nazionale Tumori, Milan, Italy, September 15-17, 2005.
74. "Creating a Collaborative Staging System for use with SEER Program/Coding System." American Joint Committee on Cancer Annual Meeting, Chicago, Illinois, September 17, 2005.
75. "Meaningfully Incorporating Nomograms Into Your Clinical Practice." Houston Urological Society, Houston, Texas, October 27, 2005.
76. "Risk Assessment and Staging of Localized Disease – Clinical Risk and Staging." American Society of Clinical Oncology, Prostate Cancer Symposium, San Francisco, California, February 24, 2006.
77. "Nomograms in Prostate Cancer." European Association of Urology 21<sup>st</sup> Annual Congress, Paris, France, April 8, 2006.
78. "Statistical Prediction Models and Medical Decision Making." Ohio State – Cleveland Clinic Foundation – Case Western Reserve University Biostatistics Joint Symposium, Columbus, Ohio, May 18, 2006.
79. "Disease Modification in MS: Decision Making...A Cancer Model." Consortium of Multiple Sclerosis Centers 20<sup>th</sup> Annual Conference, Scottsdale, Arizona, June 1, 2006.
80. "Prognostic Factors and the Use of Nomograms for Predicting Outcomes and Making Strategic Decisions in Prostate Cancer." Japanese Society of Urologic Oncology 33<sup>rd</sup> Annual Meeting, Tokyo, Japan, July 22, 2006.
81. "Treatment Decision Making in Prostate Cancer – The Use of Nomograms." The Royal Melbourne Hospital, Department of Urology, Division of Surgery 7<sup>th</sup> National Prostate Cancer Symposium, Parkville, Victoria, Australia, August 10-11, 2006.
82. "Statistical Prediction Models versus Clinical Judgment." Northwestern Medical Faculty Foundation, Inc. Grand Rounds Lecture Series, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, November 3, 2006.
83. "Prediction Models for Outcomes." University California San Francisco, Active Surveillance Conference, San Francisco, California, January 12-13, 2007.
84. "Statistical Prediction Models and Medical Decision Making." Beth Israel Deaconess Medical Center, Hematology/Oncology Grand Rounds, Boston, Massachusetts, May 16, 2007.
85. "Evaluation of Predictive Accuracy of Genetic Markers." Italian Society of Medical Statistics and Clinical Epidemiology, Naples, Italy, June 13-15, 2007.

86. "Databases for Outcomes Research." American Urological Association Foundation/Society of Basic Urologic Research Annual Summer Research Meeting, Los Angeles, California, August 2-4, 2007.
87. "Integration of Multiple Markers and Risk Factors for Diagnosis and Prognosis." International Society for Oncodevelopmental Biology and Medicine, 35<sup>th</sup> Annual Congress, Prague, Czech Republic, September 15-19, 2007.
88. "Putting Theory into Practice – analyzing diabetes care at the Cleveland Clinic using EHR." The Center for Business Intelligence (CBI) Forum on Evidence-Based Medicine, Philadelphia, Pennsylvania, December 5-6, 2007.
89. "Statistical Prediction Models and Medical Decision Making." Sunnybrooke Odette Cancer Center, Genitourinary Oncology Abbott Visiting Speaker, Toronto, Ontario, Canada, January 4, 2008.
90. "Statistical Prediction Models and Medical Decision Making." Mayo Clinic, Department of Health Sciences Research, Rochester, Minnesota, March 10, 2008.
91. "Predictive Models: Where Are We Going?" European School of Oncology, Faculty Member, Predictive Modeling in Prostate Cancer, Venice, Italy, April 17-19, 2008.
92. "Statistical Prediction Models and Medical Decision Making." Dana Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, Massachusetts, May 21, 2008.
93. "Prognostic Markers: What Improvements in Biomarkers or Imaging Would Lead to Better Prognosis/Risk Stratification? Issues in Clinical Prostate Cancer: Role of Imaging, National Cancer Institute, Rockville, Maryland, June 23-25, 2008.
94. "Nomograms in prostate cancer – why we still need them. Choosing one." The Royal Melbourne Hospital, Department of Urology, Division of Surgery 9<sup>th</sup> National Prostate Cancer Symposium, Melbourne, Victoria, Australia, August 6, 2008.
95. "Health related quality of life and prostate cancer." The Royal Melbourne Hospital, Department of Urology, Division of Surgery 9<sup>th</sup> National Prostate Cancer Symposium, Melbourne, Victoria, Australia, August 7, 2008.
96. "Health related quality of life and prostate cancer." Men's Health Promotion Forum, Prostate Cancer Foundation of Australia (PCFA), Melbourne, Victoria, Australia, August 9, 2008.
97. "Statistical models for cancer prognosis." Cancer/Biostatistics Seminar, Biostatistics Department, University of Michigan, Ann Arbor, Michigan, September 26, 2008.
98. "Predictive Models." Society of Urologic Oncology, 9<sup>th</sup> Annual Society of Urologic Oncology Meeting, Bethesda, Maryland, December 4-5, 2008.
99. "Computer Nomograms to Predict the Outcomes of Disease and Interventions." Genitourinary Cancer Conference Series, Swedish Medical Center, Seattle, Washington, January 16, 2009.
100. "Statistical Prediction Models in Urology." Urology Grand Rounds, University of Washington, Seattle, Washington, January 16, 2009.
101. "Statistical Prediction." Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark, March 23, 2009.
102. "Statistical Prediction Models and Medical Decision Making." Neue Methoden der Biometrie: 55. Biometrischen Kolloquims 2009, Leibniz University, Hannover, Germany, March 26, 2009.
103. "New Approaches to Risk Prediction." American Association for Cancer Research, 100<sup>th</sup> Annual Meeting, Denver Colorado, April 18-22, 2009.
104. "Building and Using Nomograms." Spanish Association of Urology, Third Educational Course in Urology, Madrid, Spain, May 15, 2009.
105. "Comprehensive Risk Calculator for Type 2 Diabetes Using Electronic Medical Records." Agency for Healthcare Research and Quality Comparative and Clinical Effectiveness Research Methods: II Symposium, Gaithersburg, Maryland, June 1-2, 2009.
106. "Predictive Models – Hot Topics on Bladder Part 1" XIX Congresso Nazionale SIURo, Milan, Italy, June 24, 2009.
107. "Predictive Models – Hot Topics on Prostate Part 1" XIX Congresso Nazionale SIURo, Milan, Italy, June 24, 2009.

108. “Predictive Models – Hot Topics on Kidney” XIX Congresso Nazionale SIUrO, Milan, Italy, June 26, 2009
109. “Bladder Cancer Nomograms: What We Have and What We Need” International Bladder Cancer Network, 7<sup>th</sup> Meeting, Nuernberg, Germany, October 1-3, 2009.
110. “Prediction Models in Medicine: Development, Evaluation and Implementation” Society for Medical Decision Making, 31<sup>st</sup> Annual Meeting, Hollywood, California, October 18, 2009.
111. “Predictive Models” 9<sup>th</sup> Uro-Oncology Congress, Turkish Uro-Oncology Society, Ankara, Turkey, November 4-8, 2009.
112. “Evaluation of the Incremental Value of New Biomarkers” 12<sup>th</sup> Bergmeyer Conference, International Federation of Clinical Chemistry and Laboratory Medicine, Grainau, Garmish-Partenkirchen, Germany, March 1-3, 2010.
113. “Comparative Effectiveness and Prostate Cancer” 1<sup>st</sup> Annual Michael S. Zarin Rounds, The Department of Radiation Medicine and The Smith Institute for Urology, North Shore-Long Island Jewish Health System, Great Neck, New York, April 22, 2010.
114. “Nomograms Predicting Recurrence” Management of Recurrent Disease, University of California, San Francisco, School of Medicine, Department of Radiation Oncology, San Francisco, California, April 30 – May 2, 2010.
115. “Balancing Benefit and Risk From The Patient's Perspective” Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting, San Antonio, Texas, June 5, 2010.
116. “The Prediction Philosophy. The New School of Thought in Oncology?” Societa Italiana di Urologia Oncologica (SIUrO), Rome, Italy, June 23-25, 2010.
117. “How to Treat Small Tumors: Nonsurgical Ablation” 10<sup>th</sup> International Congress on Genitourinary Malignancies, Physicians Education Resource, Washington, DC, July 16-27, 2010.
118. “Statistical Evaluation of a Novel Biomarker” 38<sup>th</sup> Annual Meeting of the International Society of Oncology and BioMarkers, Munich, Germany, September 3-8, 2010.
119. “Prediction Models for Clinical Outcomes” 4<sup>th</sup> International Consortium of Bladder Cancer Meeting, MD Anderson Cancer Center, Houston, Texas, December 2-3, 2010.
120. “Statistical Prediction Models and Medical Decision Making” Urology Grand Rounds, Henry Ford Health System, Detroit, Michigan, January 28, 2011.
121. “Using Published Nomograms to Help Individuals Make Informed Treatment Decisions” 4<sup>th</sup> Annual W. Bradford Ingalls Memorial Prostate Health and Cancer Seminar, University of Florida Prostate Disease Center, Jupiter, Florida, March 29, 2011.
122. “Design and Analysis of Cancer Prognosis Studies: Interface of Molecular Epidemiology and Clinical Research, Analysis and Modeling.” 102<sup>st</sup> Annual Meeting, American Association for Cancer Research, Orlando, Florida, April 2, 2011.
123. “Predictive Models From Bench To Bedside and Back To Bench: Construction of Predictive Tools and Measurements of Their Accuracy” 2<sup>nd</sup> Interdisciplinary Conference – Prostate Cancer: Predictive Models for Decision Making, European School of Oncology and Memorial Sloan Kettering Cancer Center, New York, New York, April 7, 2011.
124. “Prostate Cancer – Predictive Models for Decision-Making” Arkansas Prostate Cancer Foundation, University of Arkansas for Medical Science, Department of Urology/Oncology, Little Rock, Arkansas, August 30, 2011.
125. “Prediction Models for Outcomes” European School of Oncology Active Surveillance for Low Risk Prostate Cancer, Rotterdam, Netherlands, January 12, 2012.

**Permanent Study Sections:**

1. National Institutes of Health, Epidemiology of Cancer Study (EPIC) Section, Regular Member, July 1, 2008 – June 30, 2012.

**Ad Hoc Study Sections:**

1. National Institute of Diabetes and Digestive and Kidney Diseases, Prostatitis RFA, July 1997.
2. U.S. Army Ovarian Cancer Grant Review, January 1998.
3. University of Michigan SPORE in Prostate Cancer, External Advisory Board, 1999-2001.
4. National Institute of Health, Oncological Sciences IRG, November 2000.
5. National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel, January 2001
6. National Cancer Institute, Prostate Cancer Pathology Committee for Common Data Elements, April 2001.
7. National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel, July 2001.
8. National Institute of Diabetes and Digestive and Kidney Diseases, External Advisory Board, February 2002.
9. University of Nebraska SPORE in Pancreatic Cancer, External Advisory Board, 2002.
10. Urologic Diseases in America, External Advisory Committee, March 2002.
11. National Institutes of Health, Social Sciences, Nursing, Epidemiology, and Methods 4 (SNEM-4), June 2002.
12. National Institutes of Health, Interstitial Cystitis RFA, March 2003.
13. National Institutes of Health, Epidemiology of Cancer Study (EPIC) Section, Ad Hoc Reviewer, October 2007, February 2008.
14. US Army Medical Research and Materiel Command (USAMRMC) Prostate Cancer Research Program (PCRP) Integration Panel (IP), Ad Hoc Reviewer, November 2008.
15. National Institutes of Health, Center for Scientific Review, Biostatistical Methods and Research Design Study Section, Ad Hoc Reviewer, June 2009.

**Editorial Board:**

- Frontiers in Urogenital Cancer* (Editorial Board, 2011 – Present)  
*Journal of Clinical Oncology* (Editorial Board, 2011 – Present)  
*Personalized Medicine in Oncology* (Editorial Board, 2011 – Present)  
*European Urology* (Editorial Board at Large, 2010 – Present)  
*Clinical Genitourinary Cancer* (Associate Editor, 2010 – Present)  
*US Urology* (Editorial Board, 2010 – Present)  
*Annals of Urology* (Editorial Board, 2010 – 2011)  
*Cancer Investigation* (Editorial Board, 2006 – Present)  
*Nature Clinical Practice Urology* (Advisory Board, 2005 – Present)  
*Urologic Oncology: Seminars and Original Investigation* (Associate Editor, 2003-Present)  
*Medical Decision Making* (Editorial Board, 1997-2000, 2005-2008)  
*Clinical Genitourinary Cancer* (Section Editor, 2002-2009)  
*Urologic Oncology* (Associate Editor, 1999-2002)  
*Journal of Urology* (Board of Consultants, 1996-2007)

**Other:**

2001 ASCO/AACR Workshop On Methods In Clinical Cancer Research, Faculty Participant, Vail, Colorado, July 28-Aug 3, 2001.  
Quality of Life and Economic Outcomes In Localized Prostate Cancer: Consensus Conference, Faculty Participant, San Francisco, California, November 3, 2001.  
Data and Safety Monitoring Board: Minimally Invasive Surgical Therapies Consortium for Benign Prostatic Hyperplasia (MIST), 2002 – present.  
Faculty participant, The Foundation for Optimal Integrated Therapy in the Management of Prostate Cancer, U.T.M.D. Anderson Cancer Center.  
Discussant, 2<sup>nd</sup> Annual Opinion Leader Summit, St. Thomas, Jan 16 & 17, 2003.

**Publications:**

**Monographs:**

1. **Kattan MW**, editor. Encyclopedia of Medical Decision Making. Thousand Oaks, CA: Sage Publications, 2009.

**Peer-Reviewed Articles:**

1. Sharp RN, **Kattan MW**, Sharp CQ. Effects of toasting on the quality of canned rice. *J Food Sci* 1985; 50(2):340-341 & 381.
2. Brooks JR, Griffin VK, **Kattan MW**. A modified method for total carbohydrate analysis of glucose syrups, maltodextrins, and other starch hydrolysis products. *Cereal Chem* 1986; 63(5):465-466.
3. **Kattan MW**, Siebenmorgen TJ, Davis DR, McGlynn WM. A computerized system for evaluating the canning effectiveness of a thermal process: A graphical method approach. *Arkansas Farm Res* 1989;38(5):5.
4. Cronan TP, **Kattan MW**. Performance decision rules for students in an introductory information systems course: A recursive partitioning approach. *J Comp Inf Sys* 1991;21(4):77-87.
5. Nelson RR, **Kattan MW**, Cheney PH. Training, ability, and acceptance of information technology: an empirical study of its personnel and end users. *Comp Pers* 1991;13(3):20-32.
6. Liang JC, Bailey NM, Gabriel GJ, **Kattan MW**, Wang R, Fuller L, Cabanillas F, Hagemester FB. A new chemotherapy regimen for treatment of Hodgkin's disease is associated with minimal genotoxicity. *Leuk Lymphoma* 1993;9:503-508.
7. **Kattan MW**, Adams DA, Parks MS. A comparison of machine learning with human judgment. *J Manag Inf Sys* 1993;9(4):37-57.
8. Beck JR, **Kattan MW**, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. *J Urol* 1994;152:1894-1899.
9. Miles BJ, **Kattan MW**. Computer modeling of prostate cancer treatment: A paradigm for oncologic management? *Surg Oncol Clin N Am* 1995;4(2):361-372.

10. Ohori M, Wheeler TM, **Kattan MW**, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. *J Urol* 1995;154:1818-1824.
11. Goad JR, Eastham JA, **Kattan MW**, Fitzgerald KF, Collini MP, Yawn DH, Scardino PT. Radical retropubic prostatectomy: Limited benefit of autologous blood donation. *J Urol* 1995;154(6):2103-2109.
12. Eastham JA, Truong LD, Rogers E, **Kattan MW**, Flanders KD, Scardino PT, Thompson, TC. Transforming growth factor- $\beta$ 1: Comparative immunohistochemical localization in human primary and prostate cancer. *Lab Invest* 1995;73(5):628-635.
13. Goto Y, Ohori M, Arakawa A, **Kattan MW**, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies. *J Urol* 1996;156(3):1059-1063.
14. Rogers E, Gurpinar T, Dilliogluligil O, **Kattan MW**, Goad JR, Seale-Hawkins C, Carlton CE Jr, Scardino PT, Griffith DP. The role of digital rectal examination, biopsy Gleason sum and PSA in selecting patients who require pelvic lymph node dissections for prostate cancer. *Br J Urol* 1996;78:419-425.
15. **Kattan MW**, Inoue Y, Talpaz M, Ozer H, Giles F, Guilhot F, Zuffa E, Huber SL, Kantarjian HM, Beck JR. Cost-effectiveness of alpha-interferon compared to conventional chemotherapy in chronic myelogenous leukemia. *Ann Intern Med* 1996;125:541-548.
16. Yang G, Wheeler TM, **Kattan MW**, Scardino PT, Thompson TC. Perineural invasion of prostate cancer cells is associated with reduced apoptotic index. *Cancer* 1996;78(6):1267-1271.
17. Husted BW, Dozier JB, McMahon JT, **Kattan MW**. The impact of cross-national carriers of business ethics on attitudes about questionable business practices and form of moral reasoning: A social cognitive approach to global business ethics. *J Int Bus Stud* 1996;27(2):391-411.
18. Gurpinar T, Gurer S, **Kattan MW**, Wang L, Griffith DP. Laser-welded ureteral anastomoses: Experimental studies with three techniques. *Tech Uro* 1996;2(2):117-120.
19. Eastham JA, **Kattan MW**, Goad JR, Rogers E, Ohori M, Boone TB, Scardino PT. Risk factors for urinary incontinence after radical retropubic prostatectomy. *J Urol* 1996;156(5):1707-1713.
20. Cowen ME, **Kattan MW**, Miles BJ. A national survey of attitudes regarding participation in prostate carcinoma testing. *Cancer* 1996;78(9):1952-1957.
21. Marley GM, Miller MC, **Kattan MW**, Zhao G, Patton KP, Vessella RL, Wright GL Jr, Schellhammer PF, Veltri RW. Free and complexed prostate specific antigen serum (PSA) ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia (BPH). *Urology* 1996;48(6A):16-22.
22. **Kattan MW**, Stapleton AMF, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate cancer. *Cancer* 1997;79(3):528-537.
23. Henderson RJ, Eastham JA, Culkin DJ, **Kattan MW**, Whatley T, Mata J, Venable D, Sartor O. Prostate specific antigen (PSA) and PSA density are higher in african-american men without prostate cancer. *J Natl Cancer Inst* 1997;89:134-138.

24. Sutton MA, Berkman SA, Chen S-H, Block A, Dang TD, **Kattan MW**, Wheeler TM, Rowley DR, Woo SLC, Lerner SP. Adenovirus-mediated suicide gene therapy for experimental bladder cancer. *Urology* 1997;49(2):173-180.
25. Dilliogluligil O, Leibman BD, Leibman NS, **Kattan MW**, Rosas AL, Scardino PT. Risk factors for complications and morbidity after radical retropubic prostatectomy. *J Urol* 1997;157:1760-1767.
26. Soh S, Ohori M, **Kattan MW**, Wheeler TM, Scardino PT. Has there been a recent shift in the pathologic features and prognosis of patients treated with radical prostatectomy? *J Urol* 1997;157(6):2212-2218.
27. Partin AW, **Kattan MW**, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of PSA, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer: A multi-institutional update. *JAMA* 1997;277(18):1445-1451.
28. **Kattan MW**, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. *J Gen Intern Med* 1997;12:299-305.
29. Stapleton AMF, Timme TL, Gousse AE, Li Q-F, Tobon AA, **Kattan MW**, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. *Clin Cancer Res* 1997;3:1389-1397.
30. Dilliogluligil O, Leibman BD, **Kattan MW**, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. *Urology* 1997;50:93-99.
31. Eastham JA, **Kattan MW**, Groshen S, Scardino PT, Seale-Hawkins C, Rogers E, Carlton CE Jr, Lerner SP. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. *J Clin Oncol* 1997;15(10):3214-3222.
32. Gingrich JR, Barrios RJ, **Kattan MW**, Nahm HS, Finegold MJ, Greenberg NM. Androgen independent prostate cancer progression in the TRAMP model. *Cancer Res* 1997; 57:4687-4691.
33. Kim YH, **Kattan MW**, Boone TB. Correlation of urodynamic results and urethral coaptation with success after transurethral collagen injection. *Urology* 1997;50(6):941-948.
34. Stapleton AMF, Zbell P, **Kattan MW**, Yang G, Wheeler TM, Scardino PT, Thompson TC. Assessment of the biological markers p53, Ki-67, and apoptotic index as predictive indicators of prostate cancer recurrence following surgery. *Cancer* 1998;82(1):168-175.
35. Kim YH, **Kattan MW**, Boone TB. Bladder leak point pressure: the measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. *J Urol* 1998;159(2):493-497.
36. Kim YH, Goodman C, Omessie Rivera V, **Kattan MW**, Boone TB. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. *J Urol* 1998;159:972-976.

37. **Kattan MW**, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. *J Natl Ca Inst* 1998;90(10):766-771.
38. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, **Kattan MW**, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. *Clin Cancer Res* 1998 4:1873-1880.
39. Leibman BD, Dilliogluligil O, Scardino PT, Abbas F, Rogers E, Wolfinger RD, **Kattan MW**. PSA doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: A novel analysis. *J Clin Oncol* 1998;16(6):2267-2271. Reprinted in *Classic Papers and Current Comments* 2001; 6(2):273-278.
40. **Kattan MW**, Cooper RB. The predictive accuracy of computer-based classification decision techniques: A review and research directions. *Omega* 1998;26(4):467-482.
41. Hampel OZ, **Kattan MW**, Yang G, Haidacher SJ, Saleh GY, Thompson TC. Quantitative immunocytochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: A prognostic study. *J Urol* 1998;159(6):2220-2225.
42. Wheeler TM, Dilliogluligil O, **Kattan MW**, Arakawa A, Soh S, Suyama K, Ohori M, Scardino PT. Clinical and pathologic significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. *Hum Pathol* 1998;29(8):856-862.
43. Leibman BD, Abbas F, Tanli S, **Kattan MW**, Scardino PT. Impact of a clinical pathway for radical retropubic prostatectomy. *Urology* 1998;52(1):94-99.
44. Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, **Kattan MW**. The danger of applying group-level utilities to the treatment of localized prostate cancer in individual patients. *Med Decis Making* 1998;18(4):376-380.
45. **Kattan MW**, Hess KR, Beck JR. Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcome theoretical limitations of Cox proportional hazards regression. *Computers Biomed Res* 1998;31(5):363-373.
46. Hu JC, Palapattu GS, **Kattan MW**, Scardino PT, Wheeler TM. The association of selected pathological features with prostate cancer in a single needle biopsy accession. *Hum Pathol* 1998;29(12):1536-1538.
47. Miles BJ, Giesler RB, **Kattan MW**. Recall and attitudes in patients with prostate cancer. *Urology* 1999;53(1):169-174.
48. Adler HA, McCurdy MA, **Kattan MW**, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma. *J Urol* 1999;161:182-187.
49. Ohori M, Abbas F, Wheeler TM, **Kattan MW**, Scardino PT, Lerner SP. Pathologic features and prognostic significance of prostate cancer in the apical section as determined by whole mount history. *J Urol* 1999;161:500-504.

50. Kubricht WS, **Kattan MW**, Sartor O, Eastham JA. Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer. *Urology* 1999;53:553-556.
51. **Kattan MW**, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. *J Clin Oncol* 1999;17(5):1499-1507.
52. Eastham JA, May R, Robertson JL, Sartor O, **Kattan MW**. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate specific antigen between 0 and 4 ng/ml. *Urology* 1999;54:709-713.
53. Anton RC, **Kattan MW**, Chakraborty S, Wheeler TM. Postatrophic hyperplasia of the prostate. *Am J Surg Pathol* 1999;23(8):932-936.
54. Witte MN, **Kattan MW**, Albani J, Sharp DS, Eastham JA, Morton RA. Race is not an independent predictor of positive surgical margins after radical prostatectomy. *Urology* 1999;54:869-874.
55. Erdamar S, Yang G, Harper JW, Lu X, **Kattan MW**, Thompson TC. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. *Mod Pathol* 1999;12:751-755.
56. Herman CM, Wilcox GE, **Kattan MW**, Scardino PT, Wheeler TM. Lymphovascular invasion as a predictor of disease progression in prostate cancer. *Am J Surg Pathol* 2000; 24(6):859-863.
57. Blutt SE, Polek TC, Stewart LM, **Kattan MW**, Weigel NL. A calcitriol analog, EB1089, inhibits the growth of LNCaP Tumors in Nude Mice. *Cancer Research* 2000; 60:779-782.
58. Eastham JA, **Kattan MW**. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. *J Urol* 2000;163(1):143-5.
59. **Kattan MW**, Cooper RB. A simulation of factors affecting machine learning techniques: an examination of partitioning and class proportions. *Omega Int J Mgmt Sci* 2000;28:501-512.
60. Shariat SF, Bergamaschi F, Adler HL, Nguyen C, **Kattan MW**, Wheeler TM, Slawin KM. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. *Urology* 2000;56:423-429.
61. **Kattan MW**, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. *J Clin Oncol* 2000;18(19):3352-3359.
62. Cantor SB, **Kattan MW**. Determining the area under the receiver operating characteristic curve for a binary diagnostic test. *Med Decis Making* 2000;20(4):468-470.
63. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, **Kattan MW**, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H. Validation of Partin Tables for predicting pathologic stage of clinically localized prostate cancer. *J Urol* 2000;164(5):1591-1595.
64. Rabbani F, Stapleton AMF, **Kattan MW**, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. *J Urol* 2000;164(6):1929-1934.

65. Zupan B, Demsar J, **Kattan MW**, Beck JR, Bratko I. Machine learning for survival analysis: a case study on recurrence of prostate cancer. *Artif Intell Med* 2000;20(1):59-75.
66. **Kattan MW**, Fearn PA, Leibel S, Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. *Int J Radiat Oncol Biol Phys* 2000;48(5):1469-1474.
67. Sutton MA, Freund CT, Berkman SA, Dang TD, **Kattan MW**, Wheeler TM, Rowley DR, Lerner SP. In vivo Adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. *Mol Ther* 2000;2(3):211-217.
68. Slawin KM, Shariat SF, Nguyen C, Leventis AK, Weitao S, **Kattan MW**, Young CYF, Tindall DJ, Wheeler TM. Detection of metastatic prostate cancer using a spline variant-specific RT-PCR assay for human glandular Kallikrein. *Cancer Res* 2000;60(24):7142-8.
69. Giesler RB, Cowen M, Miles BJ, **Kattan MW**. Assessing quality of life in men treated for localized prostate cancer: Development of a new instrument for use in multiple settings. *Qual Life Res* 2000;9(6):645-665.
70. Wallner K, Merrick G, True L, **Kattan MW**, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low risk prostate cancer: preliminary urinary functional outcomes from a prospective randomized multicenter trial. *J Brachyther Int* 2000;16:151-155.
71. Karakiewicz PI, Scardino PT, **Kattan MW**. Related Articles, Links . The impact of sexual and urinary dysfunction on health-related quality-of-life (HRQOL) following radical prostatectomy (RP). *Prostate Cancer Prostatic Dis.* 2000 Dec;3(S1):S21.
72. Byrne RR, Shariat SF, Brown R, **Kattan MW**, Morton Jr RA, Wheeler TM, Lerner SP. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ, and lymph node metastases with long term follow-up. *J Urol* 2001;165(5):1473-1479.
73. Ross PL, Scardino PT, **Kattan MW**. A catalog of prostate cancer nomograms. *J Urol* 2001;165(5):1562-1568.
74. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, **Kattan MW**, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor  $\beta_1$  strongly predict progression in patients undergoing radical prostatectomy. *J Clin Oncol* 2001;19:2856-2864.
75. **Kattan MW**, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. *J Urol* 2001;166(1):63-67.
76. Leventis AK, Shariat SF, **Kattan MW**, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. *J Clin Oncol* 2001;19(4):1030-1039.
77. **Kattan MW**, Potters L, Blasko JC, Beyer DC, Fearn PA, Cavanagh W, Leibel S, Scardino PT. Pretreatment nomogram for predicting freedom from recurrence following permanent prostate brachytherapy in prostate cancer. *Urology* 2001;58(3):393-399.
78. Maru N, Ohori M, **Kattan MW**, Scardino PT, Wheeler TM. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. *Human Pathology* 2001;32(8):828-833.

79. Potters L, Torre T, Fearn PA, Leibel SA, **Kattan MW**. Potency after permanent prostate brachytherapy for localized prostate cancer. *Int J Rad Oncol Biol Phys* 2001;50(5):1235-1242.
80. Kothari P, Scardino P, Ohori M, **Kattan MW**, Wheeler T. Incidence, location and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. *Am J Surg Pathol* 2001;25(11):1429-1432.
81. Shariat SF, Andrews B, Kim J, **Kattan MW**, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma levels of transforming growth factor  $\beta_1$  strongly predict clinical outcome in patients with bladder carcinoma. *Cancer* 2001;92(12):2985-2992.
82. Shariat SF, Andrews B, **Kattan MW**, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. *Urology* 2001; 58(6); 1008-1015.
83. Eastham JA, Scardino PT, Yawn D, Beck R, **Kattan MW**. Preoperative autologous blood donation in retropubic prostatectomy: A cost effectiveness analysis. *Int J Healthcare Technology and Management*. 2001;3(2-4):322-336.
84. Potters L, Fearn P, **Kattan MW**. The role of external radiotherapy in patients treated with permanent prostate brachytherapy. *Prostate Cancer Prostatic Dis*. 2002;5(1):47-53.
85. Hull GW, Rabbani F, Abbas F, Wheeler TW, **Kattan MW**, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. *J Urol* 2002;167:528-534.
86. **Kattan MW**, Leung DHY, Brennan MF. A postoperative nomogram for 12-year sarcoma-specific death. *J Clin Oncol* 2002;20(3):791-796.
87. Shariat SF, Lamb DJ, **Kattan MW**, Nguyen C, Kim JH, Beck J, Wheeler TM, Slawin KM. Association of pre-operative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins -2 and -3 with prostate cancer invasion, progression, and metastasis. *J Clin Oncol* 2002;20(3):833-841.
88. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian P, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, deKernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, **Kattan MW**. A validation study of the accuracy of a postoperative nomogram for recurrence following radical prostatectomy for localized prostate cancer. *J Clin Oncol* 2002;20(3):951-956.
89. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, **Kattan MW**, Huland H. Percentage of free PSA is not an independent predictor of organ confinement or PSA recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. *J Urol* 2002;167(3):1306-1309.
90. Eastham JA, Carver B, Katz J, **Kattan MW**. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men. *Prostate* 2002;50(4):236-40.
91. Begg CB, Riedel ER, Bach PB, **Kattan MW**, Schrag D, Warren JL, Scardino PT. Variations in morbidity following radical prostatectomy. *N Engl J Med*. 2002;346(15):1138-1144.

92. Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TW, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, **Kattan MW**. Analysis of clinical stage T2 prostate cancer: Do current subclassifications represent an improvement? *J Clin Oncol*. 2002;20(8):2025-2030.
93. Potters L, Fearn P, **Kattan MW**. The role of external radiotherapy in patients treated with permanent prostate brachytherapy. *Prostate Cancer and Pros Dis*. 2002;5(1):47-53.
94. Lee LN, Barnswell C, Torre T, Fearn P, **Kattan MW**, Potters L. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: Multivariate and matched-pair analyses. *Int. J. Radiation Oncology. Biol. Phys.* 2002;53(2):282-289.
95. Potters L, Fearn P, **Kattan MW**. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. *Brachytherapy*. 2002;1(1):36-41.
96. Lee LN, Barnswell C, Torre T, Fearn P, **Kattan MW**, Potters L. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy multivariate and matched-pair analyses. *Int J Radiat Oncol Biol Phys*. 2002 Jun 1;53(2):282-289.
97. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino PT, **Kattan MW**. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. *Urologic Oncology*. 2002;7(4):141-146.
98. Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schroeder FH, Wildhagen MF, van der Kwast TT, Scardino PT, **Kattan MW**. International validation of a preoperative nomogram for prostate cancer recurrence following radical prostatectomy. *J Clin Oncol*. 2002;20(15):3206-3212.
99. Coakley FV, Wei DC, **Kattan MW**, Eberhardt S, Scardino PT, Hricak H. Urinary continence after radical retropubic prostatectomy: relationship to membranous urethral length on preoperative endorectal MR imaging. *J Urol* 2002;168(3):1032-1035.
100. Smaletz O, Scher H, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, **Kattan MW**. Nomogram for overall survival of patients with progressive metastatic prostate cancer following castration. *J Clin Oncol* 2002;20(19):3972-3982.
101. Shariat SF, Gottenger E, Nguyen C, Song W, **Kattan MW**, Andenorol J, Wheeler TM, Spencer DM, Slawin, KM. Preoperative blood RT-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. *Cancer Research* 2002;62:5974-5979.
102. **Kattan MW**, Scardino PT. Prediction of progression: nomograms of clinical utility. *Clinical Prostate Cancer* 2002;1(2):90-96.
103. Knight SJ, Nathan DP, Siston AK, **Kattan MW**, Elstein AS, Collela KM, Wolf MS, Slimack NS, Bennett CL, Golub RM. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. *Clinical Prostate Cancer* 2002;1(2):105-114.

104. Potters L, Purrazzella R, Brustein S, Fearn, PA, Leibel SA, **Kattan MW**. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate cancer. *Cancer* 2002;95(7):1451-1456.
105. Yossepowitch O, Ohori M, Sircari K, **Kattan MW**, Scardino PT, Wheeler TM, Reuter VE. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. *J Urol.* 2002;168(5):2011-2015.
106. McKiernan J, Yossepowitch O, **Kattan MW**, Simmons R, Motzer RJ, Reuter VE, Russo P. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. *Urology* 2002;60(6):1003-1009.
107. Knudsen, BS, Gmyrek, GA, Inra J, Scherr DS, Vaughn ED, Nanus DM, **Kattan MW**, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. *Urology* 2002;60(6):1113-1119.
108. Ross PL, Littenberg B, Fearn P, Scardino PT, Karakiewicz PI, **Kattan MW**. Paper standard gamble: a paper-based measure of standard gamble utility for current health. *Int J Technol Assess Health Care* 2003;19(1):135-147.
109. Karakiewicz PI, **Kattan MW**, Tanguay S, Elhilali MM, Bazinet M, Scardino PT and Aprikian AG. Cross cultural validation of the UCLA Prostate Cancer Index. *Urology* 2003;61(2):302-7.
110. Ohori M, **Kattan MW**, Utsunomiya T, Suyama K, Scardino PT, and Wheeler TM. Do impalpable (T1c) prostate cancers visible on ultrasound differ from those not visible? *J Urol* 2003;169(3):964-8.
111. Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, **Kattan MW**, Scardino PT, Huland E, Huland H, Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. *Prostate.* 2003; 15:54(3):181-6.
112. Bach PB, **Kattan MW**, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh, LJ, and Begg CB. Variations in lung cancer risk among smokers. *J Natl Cancer Inst* 2003;95:470-478.
113. Shariat SF, **Kattan MW**, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific RT-PCR assay for human glandular kallikrein. *J Clin Oncol* 2003; 21(7):1223-1231.
114. Halabi S, Small EJ, Kantoff PW, **Kattan MW**, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone refractory metastatic prostate cancer. *J Clin Oncol* 2003; 21(7):1232-1237.
115. Patel MI, Simmons R, **Kattan MW**, Motzer R, Reuter V, and Russo P. Long term follow up of bilateral sporadic renal tumors. *Urology* 2003;610(5):921-925.
116. **Kattan MW**, Eastham JA. Algorithms for PSA recurrence after treatment of localized prostate cancer. *Clinical Prostate Cancer* 2003;1:221-226.

117. Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Cagiannos I, Scardino PT, **Kattan MW**, and Huland H. Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy (in German). *Urologe A* 2003;42(5):685-92.
118. Bianco FJ Jr, **Kattan MW**, Scardino PT, Powell IJ, Pontes JE, Wood DP Jr, Moul JW. Radical prostatectomy nomograms in black American men: accuracy and applicability. *J Urol* 2003;170(1):73-77.
119. Potters L, Purrazzella R, Brustein S, Fearn P, Huang D, Leibel SA, **Kattan MW**. The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 2003; 1:56(3):749-54.
120. Lee CT, Genega EM, Hutchinson B, Fearn PA, **Kattan MW**, Russo P, Reuter VE. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. *Urol Oncol* 2003; 21(3):179-84.
121. Aleman M, Karakiewicz PI, Kupelian P, **Kattan MW**, Graefen M, Cagiannos I, Eastham J, Scardino PT, Huland H, Klein EA. Age and PSA predict the likelihood of organ-confined disease in men presenting with PSA < 10 Ng/ml: implications for screening. *Urology* 2003; 62(1):70-4.
122. Potters L, **Kattan MW**, Fearn P. A chronological database to support outcomes research in prostate cancer. *Int J Radiat Oncol Biol Phys* 2003; 56(5):1252-1258.
123. Shariat SF, Roudier MP, Wilcox GE, **Kattan MW**, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM: Comparison of immunohistochemistry with RT-PCR for the detection of micrometastatic prostate cancer in lymph nodes. *Cancer Res.* 2003 Aug 1;63(15):4662-70.
124. Koh H, **Kattan MW**, Scardino PT, Suyama K, Maru N, Slawin K, Wheeler TM, Ohori M. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. *J Urol* 2003; 170(4): 1203-1208.
125. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, and **Kattan MW**. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. *J Urol* 2003; 70(4): 1184-1188: Oct 2003.
126. **Kattan MW**, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Scardino PT, Ohori M, Wheeler TM, Slawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor B1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. *J Clin Oncol* 2003; 21(19): 3573-3579.
127. **Kattan MW**, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival following an r0 resection for gastric carcinoma. *J Clin Oncol* 2003; 21(19): 3647-3650.
128. Shariat, S, **Kattan MW**, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM. (2003). Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. *Cancer Res* 2003; 63: 5874-5878.

129. Solit DB, Morris M, Slovin S, Curley T, Schwartz L, Larson S, **Kattan MW**, Hartley-Asp B, Scher HI, Kelly WK. Clinical experience with intravenous estramustine phosphate, paclitaxel and carboplatin in patients with castrate metastatic prostate adenocarcinoma. *Cancer* 2003; 98(9): 1842-1848.
130. **Kattan MW**, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. *Stat Med* 2003; 22: 3515-3525.
131. **Kattan MW**, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *J Urol* 2003; 170: 1792-1797.
132. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT and **Kattan MW**. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. *J Urol* 2003; 170: 1798-1803.
133. **Kattan MW**. Comparison of Cox regression with other methods for determining prediction models and nomograms. *J Urol* 2003; 170: S6-S10.
134. Zakian KL, Eberhardt S, Hricak H, Shukla-Dave A, Kleinman S, Muruganandham M, Sircar K, **Kattan MW**, Reuter V, Scardino P, Koutcher JA. Transition zone prostate cancer: metabolic characteristics at H MR spectroscopic imaging—initial results. *Radiology* 2003; 229(1): 241-247.
135. Eastham JA, **Kattan MW**, Riedel E, Begg C, Wheeler T, Gerigk C, Gonen M, Reuter V, Scardino PT. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. *J Urol* 2003; 170:2292-2295.
136. Van Zee KJ, Manasseh DE, Bevilacqua JLB, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody III HS, **Kattan MW**. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. *Annals of Surgical Oncology* 2003; 10(10): 1140-1151.
137. Littenberg B, Partilo S, Licata A, **Kattan MW**. Paper Standard Gamble: The reliability of a paper questionnaire to assess utility. *Medical Decision Making* 2003; 23(6): 480-488.
138. **Kattan MW**, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, Leibel SA. A pretreatment nomogram that predicts 5 year probability of metastasis following 3-D conformal radiation therapy for localized prostate cancer. *J Clin Oncol* 2003; 21(24):4568–4571.
139. **Kattan MW**. Comparing treatment outcomes using utility assessment for health-related quality of life. *Oncology* 2003; 17(12): 1687-1693.
140. Beck SDW, Patel MI, Snyder ME, **Kattan MW**, Motzer RJ, Reuter VE, Russo P. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. *Ann Surg Oncol* 2003; 11(1):71-77.

141. Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Erbersdobler A, Henke RP, Huland H, Wheeler TM, Slawin K, Scardino PT, **Kattan MW**. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. *J Urol* 2004 Jan; 171(1):200-203
142. Hu JC, Elkin EP, Pasta DJ, Lubeck DP, **Kattan MW**, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. *J Urol* 2004; 171(2):703-708.
143. Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer P, Erbersdobler A, Schroeder F, Wildhagen M, Quinn DI, Henashall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, **Kattan MW**. Is year of radical prostatectomy a predictor of outcome in prostate cancer? *J Urol* 2004; 171:692-696.
144. Richstone L, Scherr DS, Reuter VR, Snyder ME, Rabbani F, **Kattan MW**, Russo P. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. *J Urol* 2004; 171(2): 615-620.
145. Di Blasio C, **Kattan MW**. Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. *Urology* 2004; 62: 9-18.
146. Scher HI, Eisenberger M, D\_Amico AV, Halabi S, Small EJ, Morris M, **Kattan MW**, Roach M, Kantoff P, Pienta KJ, Carducci MA, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* 2004; 22(3): 537-556.
147. **Kattan MW**. Evaluating a new marker's predictive contribution. *Clin Can Res* 2004; 10: 822-824.
148. DiBlasio DJ, Snyder ME, **Kattan MW**, Russo P. Ketorolac: safe and effective analgesia in the management of renal cortical tumors with partial nephrectomy. *J Urol* 2004; 171: 1062-1065.
149. Stephenson AJ, Shariat SF, Zelefsky MJ, **Kattan MW**, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, and Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA* 2004 Mar 17; 291(11):1325-1332.
150. Shariat SF, **Kattan MW**, Andrews B, Zhu K, Traxel E, Wheeler TM and Slawin KM. Association of pre- and post-operative plasma levels of transforming growth factor  $\beta$ 1, and interleukin-6 and its soluble receptor with prostate cancer progression. *Clin Cancer Res* 2004; 10: 1992-1999.
151. Potters L, Klein EA, **Kattan MW**, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA. Monotherapy for stage T1/T2 Prostate Cancer: radical prostatectomy, external beam radiotherapy, or permanent prostate brachytherapy. *Radioth Oncol* 2004; 71(1): 29-33.
152. Ohori M, **Kattan MW**, Koh H, Maru N, Slawin KM, Shahrokh S, Muamamoto M, Reuter VE, Wheeler TM, Scardino PT. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. *J Urol* 2004 May; 171(5):1844-1849 .

153. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, **Kattan MW**, Wallace K, Carroll PR. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (CAPSURE). *J Urol.* 2004 Jun;171(6, Part 1 Of 2):2255-2259.
154. Boccon-Gibod, L, Djavan B, Hammerer P, Hoeltl W, **Kattan MW**, Prayer-Galetti T, Teillac P, and Tunn UW. Management of PSA relapse in prostate cancer: a European consensus. *Int J Clin Pract* 2004 Apr;58(4):382-90.
155. Singh H, Karakiewicz P, Shariat SF, Canto EI, Nath RK, **Kattan MW**, and Slawin KM. Impact of unilateral interposition sural nerve grafting on recovery of urinary function after radical prostatectomy. *Urology.* 2004 Jun;63(6):1122-7.
156. Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE, Gonen V, **Kattan MW**, Onyebuchi CN, Scardino PT. The role of preoperative endorectal MRI in the decision whether to preserve or resect the neurovascular bundles during radical retropubic prostatectomy. *Cancer.* 2004 Jun 15;100(12):2655-63.
157. Mullerad M, Hricak H, Wang L, Chen H, **Kattan MW**, Scardino P. Prostate Cancer: Detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. *Radiology* 2004 Jul;232(1):140-146.
158. Karakiewicz PI, Tanguay S. **Kattan MW**, Elhilali MM, Aprikian AG. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men. *Eur Urol.* 2004 Aug;46(2): 188-94.
159. Mullerad M, Hricak H, Wang L, Chen HN, **Kattan MW**, Scardino PT. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. *Radiology.* 2004 July;232(1):140-146.
160. Brennan MF, **Kattan MW**, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. *Ann Surg.* 2004 Aug;240(2): 293-8.
161. Bochner BH, Cho D, Herr HW, Donat M, **Kattan MW**, Dalbagni G. Prospectively packaged lymph node dissections with radical cystectomy: Evaluation of node count variability and node mapping. *J Urol.* 172(4, Part 1 of 2):1286-1290, October 2004.
162. **Kattan MW**, Vickers AJ. Incorporating predictions of individual patient risk in clinical trials. *Urol Oncol.* 2004 Jul-Aug;22(4):348-52.
163. Secin FP, Carver B, **Kattan MW**, and Eastham JA. Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate? *Transplantation.* 2004 Sept 15;78(5):710-2.
164. Elkin EB, Cowen ME, Cahill D, Steffel M, **Kattan MW**. Preference assessment method affects decision analytic recommendations: a prostate cancer treatment example. *Med Dec Making.* 2004 Sep-Oct;24(5):504-10.
165. Carver BS, Bozeman CV, Simoneaux WJ, Venable DD, **Kattan MW**, Eastham JA. Race is not a predictor of prostate cancer detection on repeat prostate biopsy. *J. Urol.* 2004 Nov 172(5 Part 1 of 2):1853-1855.

166. Eilber FC, Brennan MF, Eilber FR, Singer S, and **Kattan MW**. Validation of the postoperative nomogram for 12-year sarcoma-specific death. *Cancer*. 2004 Oct 13;101(10): 2270-2275.
167. Karakiewicz PI, Tanguay S, **Kattan MW**, Elhilali MM, Aprikian, AG. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men. *Eur Urol*. 2004 Aug;46(2) 188-194.
168. Mullerad M, Russo P, Golijanin D, Chen HN, Tsai HH, Donat SM, Bochner BH, Herr HW, Sheinfeld J, Sogani PC, **Kattan MW**, Dalbagni G. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. *J. Urol*. 2004 Dec;172(6 Pt 1):2177-2181.
169. **Kattan MW**, Giri D, Panageas KS, Hummer A, Cranor M, Van Zee KJ, Hudis CA, Norton L, Borgen PI, Tan LK. A tool for predicting breast cancer death in women who do not receive adjuvant therapy. *Cancer*. 2004 Dec 1;101(11):2509-15.
170. Bach PB, Elkin EG, Pastorino U, **Kattan MW**, Mushlin AI, Begg CB, Parkin DM. Benchmarking lung cancer mortality rates in current and former smokers. *Chest*. 2004 Dec;126(6):1742-9.
171. Mariani L, Miceli R, **Kattan MW**, Brennan MF, Colecchia M, Fiore M, Casali PG, Gronchi A. Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system. *Cancer*. 2005 Jan 15;103(2):402-408.
172. Sorbellini M, **Kattan MW**, Snyder ME, Goetzel M, McKiernan J, Russo P: A post operative nomogram predicting recurrence for patients with conventional clear-cell renal cell carcinoma. *J Urol*. 2005 Jan;173(1):48-51.
173. Yanke BV, Gonen M, Scardino PT, **Kattan MW**. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. *J Urol*. 2005 Feb;173(2):421-424.
174. Carver BS, **Kattan MW**, Scardino PT, Eastham JA. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. *BJU Int*. 2005 Mar;95(4):509-12.
175. Peeters KCMJ, **Kattan MW**, Hartgrink HH, Kraneberg EK, Karpeh MS, Brennan MF, van de Velde CJH. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. *Cancer*. 2005 Feb 15;103(4):702-707.
176. Zakian KL, Sircar K, Hricak H, Chen H, Shukla-Dave A, Eberhardt S, Muruganandham M, Eboral L, **Kattan MW**, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with Gleason score based on step section pathology after radical prostatectomy. *Radiology*. 2005 Mar;234(3):804-14.
177. Haese A, Vaisanen V, Lilja H, **Kattan MW**, Rittenhouse HG, Petterson K, Chan DW, Huland H, Sokoll LJ, Partin AW. Comparison of predictive accuracy for pathologically organ-confined prostate cancer in clinical stage T1c patients using levels of human glandular kallikrein 2 and prostate-specific antigen in combination with clinical state and Gleason Grade. *J. Urol*. 2005 Mar;173(3):752-6.

178. Dotan ZA, Bianco Jr FJ, Rabbani R, Eastham JA, Fearn P, Scher HI, Kelly KW, Chen HN, Schoder H, Hricak H, Scardino PT, **Kattan MW**. The pattern of PSA failure dictates the probability of a positive bone scan in patients with a rising PSA after radical prostatectomy. *J. Clin Oncol.* 2005 Mar20;23(9):1962-8.
179. **Kattan MW**. When and how to use informatics tools in caring for urologic patients. *Nature Clin Practice Urol.* Apr 2005; 2(4):183-190.
180. Stephenson AJ, Bosl GJ, Motzer RJ, **Kattan MW**, Stasi J, Bajorin DF, Sheinfeld J. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. *J Clin Oncol.* Apr 2005; 23(12):2781-2788.
181. Steuber T, Haese A, Niemela P, Pettersson K, Graefen M, Hammerer P, **Kattan MW**, Huland H, Lilja H. Association of free-Prostate Specific Antigen subfractions with volume of benign and malignant prostatic tissue. *Prostate* . 2005 Apr 1;63(1):13-18.
182. Wong SL, **Kattan MW**, McMasters KM, Coit DG. A nomogram that predicts presence of sentinel lymph node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer (AJCC) staging system. *Ann Surg Oncol.* 2005 Apr; 12(4):282-288.
183. Mallah KN, DiBlasio CJ, Rhee AC, Scardino PT, **Kattan MW**. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate cancer treated with radical prostatectomy. *Cancer.* 2005 May 15;103(10):2030-2034.
184. Karakiewicz PI, Benayoun S, **Kattan MW**, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. *J Urol.* 2005 Jun; 173(6): 1930-1934.
185. Isom-Batz G, Bianco FJ, Jr., **Kattan MW**, Mulhall JP, Lilja H, Eastham JE. Testosterone as a predictor of pathologic stage in clinically localized prostate cancer. *J Urol.* 2005 Jun; 173(6):1935-1937.
186. Bianco FJ, Jr., Riedel ER, Begg CB, **Kattan MW**, Scardino PT. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. *J Urol.* 2005 Jun; 173(6):2099-2103.
187. Saranchuk JW, **Kattan MW**, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. *J Clin Oncol.* June 2005;23(18):4146-4151.
188. Stephenson AJ, Smith A, **Kattan MW**, Satagopan J, Reuter VE, Scardino PT, Gerald WL. Integration of gene expression profiling and clinical variables to predict prostate cancer recurrence after radical prostatectomy. *Cancer.* July 15, 2005;104(2):290-298.
189. Mullerad M, Bochner, BH, Adusumilli PS, Bhargava A, Kikuchi E, Hui-Ni C, **Kattan MW**, Chou TC, Fong Y. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. *J Urol.* 2005 Aug;174(2):741-746.
190. Specht MC, **Kattan MW**, Gonen M, Fey J, Van Zee KJ. Predicting non-sentinel node status after a positive sentinel node biopsy for breast cancer: Clinicians versus nomogram. *Ann Surg Oncol.* 2005 Aug;12(8):654-659.

191. Swindle P, Eastham JA, Ohori M, **Kattan MW**, Wheeler T, Maru N, Slawin K, Scardino PT. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. *J Urol*. 2005 Sep;174(3):903-907.
192. Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr. FJ, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, **Kattan MW**. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J. Clin Oncol*. 2005 Oct 1; 23(28):7005-7012.
193. Befort CA, Zelefsky MJ, Scardino PT, Borrayo E, Giesler RB, **Kattan MW**. A measure of health-related quality of life among localized prostate cancer patients: result from on-going scale development. *Clin Prostate Cancer*. 2005 Sept;4(2):100-108.
194. Ferrone CR, **Kattan MW**, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL. Validation of a post-resection pancreatic adenocarcinoma nomogram for disease specific survival. *J Clin Oncol*. 2005 Oct 20;23(30):7529-7535.
195. Karakiewicz PI, Eastham JA, Graefen M, Cagiannos I, Stricker PD, Klein E, Cangiano T, Schroder FH, Scardino PT, **Kattan MW**. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. *Urology*. 2005 Dec;66(6):1245-1250.
196. Tsuboi T, Ohori M, Kuroiwa K, Reuter VE, **Kattan MW**, Eastham JA, Scardino PT. Are intraoperative frozen sections an efficient way to reduce positive surgical margins? *Urology*. 2005 Dec;66(6):1287-1291.
197. Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, **Kattan MW**, Scardino PT. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. *J. Urol*. 2005 Dec;174(6):2158-2163.
198. Novotny AR, Schuhmacher C, Busch R, **Kattan MW**, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. *Ann Surg*. 2006 Jan;243(1):74-81.
199. Slawin KM, **Kattan MW**, Roehrborn CG, Wilson T. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. *Urol*. 2006 Jan;67(1):84-88.
200. Cowen ME, Halsyamani LK, **Kattan MW**. Predicting life expectancy for men with clinically localized prostate cancer. *J Urol*. 2006 Jan;175(1):99-103.
201. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. *Radiology* 2006 Feb;238(2):597-603.
202. Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FKH, **Kattan MW**, Eastham JA, Scardino PT, Huland H, Lilja J. Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. *Int J Cancer*. 2006 Mar 1;118(5):1234-1240.

203. Lopez-Carona E, Ohori M, Wheeler TM, Reuter VE, Scardino PT, **Kattan MW**, Eastham JA. Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate. *J Urol*. 2006 Mar;175(3):923-927.
204. Wang L, Hricak H, **Kattan MW**, Schwartz LH, Eberhardt S, Chen HN, Scardino P. Combined endorectal and phased array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. *AJR Am J Roentgenol*. 2006 Mar;186(3):743-748.
205. **Kattan MW**. Measuring hot flashes in men treated with hormone ablation therapy: an unmet need. *Urol Nurs*. 2006 Feb;26(1):13-18.
206. Ficarra V, Zattoni F, Artibani W, Fandella A, Martignoni G, Novara G, Prayer-Galetti T, Zambolin T, **Kattan MW**, GUONE Penile Cancer Project Members. Nomogram predictive of pathological inguinal lymph node involvement in patients with squamous cell carcinoma of the penis. *J Urol*. 2006 May;175(5):1700-1705.
207. Stephenson AJ, Scardino PT, Eastham JA, Bianco, JR FJ, Dotan ZA, Fearn PA, **Kattan MW**. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *JNCI*. 2006 May 17;98(10):715-717.
208. **Kattan MW**, Ficarra V, Artibani W, Cosciani Cunico S, Fandella A, Martignoni G, Novara G, Prayer Galetti T, Zattoni F and GUONE Penile Cancer Project Cancer Project Members. Nomogram predictive of cancer-specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. *J Urol*. 2006 Jun;175(6):2103-2108.
209. Teh BS, Batasch MD, Mai WY, **Kattan MW**, Butler EB, Kadmon D. Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. *J Urol*. 2006 Jun;175(6):2097-2102.
210. Ramirez A, Benayoun S, Briganti A, Chun J, Perrotte P, **Kattan MW**, Graefen M, McCormack M, Neugut AI, Saad F, Karakiewicz PI. High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. *Eur Urol*. 2006 Jul 1;50(1):58-63.
211. Hammerer PG, **Kattan MW**, Mottet N, Prayer-Galetti T. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. *BJU Int*. 2006 July;98(1):11-19.
212. Mottet N, Prayer-Galetti T, Hammerer P, **Kattan MW**, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. *BJU Int*. 2006 July;99(1):20-27.
213. Schachter LR, Bach AM, Snyder ME, **Kattan MW**, Russo P. The impact of tumor location on histological subtype of renal cortical tumors. *BJU Int*. 2006 Jul;98(1):63-66.
214. Sorbellini M, **Kattan MW**, Snyder ME, Hakimi AA, Sarasohn DM, Russo P. Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. *J Urol*. 2006 Aug;176(2):472-476.
215. Elkin EB, Vickers AJ, **Kattan MW**. Primer: using decision analysis to improve clinical decision making in urology. *Nat Clin Pract Urol*. 2006 Aug;3(8):439-448.

216. Bochner BH, **Kattan MW**, Vora KC, International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. *J Clin Oncol.* 2006 Aug;24(24):3967-3972.
217. Stephenson AJ, **Kattan MW**, Eastham JA, Dotan ZA, Bianco FJ, Lilja H, Scardino PT. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. *J Clin Oncol.* 2006 Aug;24(24):3973-3978.
218. Dalal KM, **Kattan MW**, Atonescu CR, Brennan MF, Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. *Ann Surg.* 2006 Sep;244(3):381-391.
219. Cuzick J, Fisher G, **Kattan MW**, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino PT on behalf of the Transatlantic Prostate Group. Long-term outcome among men with conservatively treated localized prostate cancer. *Br J Cancer.* 2006 Nov 6;95(9):1186-94.
220. White RR, **Kattan MW**, Haney JC, Clary BM, Pappas TN, Tyler DS, Brennan MF. Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. *Ann Surg Oncol.* 2006 Nov 13(11):1485-1492.
221. Snyder ME, Bach A, **Kattan MW**, Raj GV, Reuter VE, Russo P. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. *J Urol.* 2006 Dec;176(6):2391-2396.
222. Roach M 3<sup>rd</sup>, Weinberg V, Nash M, Sandler HM, McLaughlin PW, **Kattan MW**. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. *J Urol.* 2006 Dec;176(6S):S16-S20.
223. Fu A, **Kattan MW**. Racial and ethnic differences in preference-based health status measure. *Curr Med Res Opin.* 2006 Dec;22(12):2439-2448.
224. Steyerberg EW, Roobol MJ, **Kattan MW**, van der Kwast TH, de Koning HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. *J. Urol.* 2007 Jan;177(1):107-112.
225. Wang, L, Hricak H, **Kattan MW**, Chen HN, Kuroiwa K, Eisenberg HF, Scardino PT. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. *Radiology.* 2007 Jan (1):182-188.
226. Steuber T, Vickers A, Haese A, **Kattan MW**, Eastham JA, Scardino PT, Huland H, Lilja H. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. *Int J Cancer.* 2007 Jan 4;120(7):1499-1504.
227. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, **Kattan MW**, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor in castration-resistant prostate cancer after progression from taxane-based therapy. *J Clin Oncol.* 2007 Feb 20; 25(6):675-681
228. Bianco FJ, Mallah KN, Korets R, Hricak H, Scardino PT, **Kattan MW**. Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer. *Urology.* 2007 Feb;69(2):343-346.

229. Sekeres M, **Kattan MW**, Maciejewski J, Kalaycio M, Fu Z, Golshayan A. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. *Cancer*. 2007 Mar 15;109(6):1125-1132.
230. Baccala A Jr, Reuther AM, Bianco FJ Jr, Scardino PT, **Kattan MW**, Klein EA. Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival: multi-institutional study of 6740 patients. *Urology*. 2007 Mar;69(3):536-540.
231. Steuber T, Vickers A, Haese A, **Kattan MW**, Eastham JA, Scardino PT, Huland H, Lilja H. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor n serum improve selection of patients for prostate cancer biopsy. *Int J Cancer*. 2007 Apr 1;120(7):1499-1504.
232. Chun FK, Karakiewicz PI, Briganti A, Walz J, **Kattan MW**, Huland H, Graefen M. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. *BJU Int*. 2007 April;99(4):794-800.
233. Shukla-Dave A, Hricak H, **Kattan MW**, Pucar D, Kuriowa K, Chen HN, Spector J, Koutcher JA, Zakian KL, Scardino PT. Utility of magnetic resonance imaging and spectroscopy in prediction of insignificant prostate cancer – initial analyses. *BJU Int*. 2007 Apr;99(4):786-793.
234. Golshayan AR, Jin T, Maciejewski J, Fu AZ, Bershadsky B, **Kattan MW**, Kalaycio ME, Sekeres MA. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. *Br J Haematol*. 2007 Apr;137(2):125-132.
235. Kibel AS, Rosenbaum E, **Kattan MW**, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy: a multi-institutional pilot study. *J Urol*. 2007 May;177(5):1777-1781.
236. Stephenson AJ, Scardino PT, **Kattan MW**, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roerhborn CG, Catton CN, De Weese TL, Liaus SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol*. 2007 May;25(15):2035-2041.
237. Vickers AJ, **Kattan MW**, Sargent D. Method for evaluating prediction models that apply the results of randomized trials to individual patients. *Trials*. 2007 June 5;8(1):14.
238. Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR Jr, Frank I, Perpongkosol S, Weight CJ, Kaouk JH, **Kattan MW**, Novick AC. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. *J Urol*. 2007 July;178(1):41-46.
239. Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM, Sapir M, Bayer-Zubeck V, Vengrenyuk Y, Fogarsi S, Saidi O, Reuter VE, Scher HI, **Kattan MW**, Bianco FJ, Wheller TM, Ayala GE, Scardino PT, Donovan MJ. Improved prediction of prostate cancer recurrence through systems pathology. *J Clin Invest*. 2007 July;117(7):1876-1883.

240. Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, **Kattan MW**, Edson JE, Scardino PT. The surgical learning curve for prostate cancer control after radical prostatectomy. *J Natl Cancer Inst.* 2007 Aug 1;99(15):1171-1177.
241. Lane BR, Babineau D, **Kattan MW**, Novick AC, Gill IS, Zhou M, Weight CJ, Campbell SC. A preoperative prognostic nomogram for solid enhancing renal tumors 7cm or less amenable to partial nephrectomy. *J. Urol.* 2007 Aug;178(2):429-434.
242. Bevilacqua JLB, **Kattan MW**, Fey JV, Cody HS, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. *J Clin Oncol.* 2007 Aug 20;25(24):3670-3679.
243. Nam RK, Toi, A, Klotz LK, Trachtenberg J, Jewett MAS, Appu S, Loblaw DA, Sugar L, Narod SA, **Kattan MW**. Assessing individual risk for prostate cancer. *J Clin Oncol.* 2007 Aug 20;25(24):3582-3588.
244. Heller G, **Kattan MW**, Scher HI. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data. *Med Decis Making.* 2007, Jul-Aug;27(4):380-386.
245. Zelefsky MJ, **Kattan MW**, Fearn PA, Fearon BL, Stasi JP, Shippy AM, Scardino PT. Pre-treatment nomogram predicting the 10-year biochemical outcome of three-dimensional conformal radiotherapy and intensity modulated radiotherapy for prostate cancer. *Urology.* 2007, Aug;70(2):283-287.
246. Lucia MS, Epstein JI, Goodman PH, Darke AK, Reuter VE, Civantos F, Tangen CM, Howard PH, Parnes L, Lippman SM, LaRosa RG, **Kattan MW**, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the PCPT. *J Natl Cancer Inst.* 2007, Sep 19;99(18):1375-1383.
247. Berney DM, Fisher G, **Kattan MW**, Oliver RTD, Møller, Fearn P, Eastham J, Scardino PT, Cuzick J, Reuter VE, Foster, CS. Pitfalls in the diagnosis of prostate cancer: retrospective review of 1791 cases with clinical outcome. *Histopathology.* 2007, Oct;51(4):452-457.
248. Eilber FC, **Kattan MW**. Sarcoma nomogram: validation and a model to evaluate impact of therapy. *J Am Coll Surg.* 2007;205(4):S90-S95.
249. Roemeling S, Roobol MJ, **Kattan MW**, van der Kwast TH, Steyerberg EW, Schröder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. *Cancer.* 2007 Nov 15;110(10):2218-2221.
250. Berney DM, Fisher G, **Kattan MW**, Oliver RTD, Møller, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter, VE, Foster CS. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. *BJU Intl.* 2007, Dec;100(6):1240-1244.
251. Lauer MS, Pothier CE, Magid DJ, Smith SS, **Kattan MW**. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. *Ann Intern Med.* 2007 Dec 18;147(12):821-828.

252. Stone NN, Potters L, David BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, **Kattan MW**. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. *Int J Radiat Oncol Biol Phys*. 2007 Dec 1;69(5):1472-1477.
253. Heath EI, **Kattan MW**, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti, Jr. JC, Amling CL, Freedland SJ. The effect of race/ethnicity on the accuracy of the 2001 Partin tables for predicting pathologic stage of localized prostate cancer. *J Urol*. 2008 Jan;71(1):151-155.
254. **Kattan MW**, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino PT; and the Transatlantic Prostate Group. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. *Cancer*. 2008 Jan 1;112(1):69-74.
255. Chi DS, Palayekar MJ, Sonoda Y, Abu-Rustum NR, Awtrey CS, Huh J, Eisenhauer EL, Barakat RR, **Kattan MW**. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. *Gynecol Oncol*. 2008 Jan;108(1):191-194.
256. Weiser MR, Landmann RG, **Kattan MW**, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. *J Clin Oncol*. 2008 Jan 20;26(3):380-385.
257. Cho CS, Gönen M, Shia J, **Kattan MW**, Klimstra DS, Jarnagin WR, D'Angelica MI, Blumgart LH, DeMatteo RP. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. *J Am Coll Surg*. 2008 Feb;206(2):281-291.
258. **Kattan MW** Gönen M, Jarnagin WR, DeMattero R, D'Angelica M, Weiser M, Blumgart LH, Fong Y. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. *Ann Surg*. 2008 Feb;247(2):282-287.
259. Eastham JA, **Kattan MW**, Fearn P, Fisher G, Berney DM, Oliver T, Foster CS, Møller H, Reuter V, Cuzick J, Scardino PT and the Transatlantic Prostate Group. Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. *Eur Urol*. 2008 Feb;53(2):347-354.
260. Orthuber W, Fiedler F, **Kattan MW**, Sommer T, Fischer-Brandies H. Design of a global medical database which is searchable by human diagnostic patterns. *The Open Medical Informatics Journal*. 2008, 2:21-31.
261. Richstone L, Bianco FJ, Shah H, **Kattan MW**, Eastham JA, Scardino PT, Scherr D. Radical prostatectomy in men seventy years or older: impact of age on upgrading upstaging and preoperative nomogram accuracy. *BJU Intl*. 2008 Mar;101(5):541-546.
262. Karakiewicz PI, Bhojani N, Neugut A, Shariat SF, Jeldres C, Graefen M, Perrotte P, Ploquin F, **Kattan MW**. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. *J Sex Med*. 2008 Apr;5(4):919-927.
263. Vickers AJ, Kwang Jang BS, Sargent D, Lilja H, **Kattan MW**. A systematic review of statistical methods in molecular marker studies in cancer. *Cancer*. 2008 April 15;112(8):1862-1868.

264. Swindle P, Eastham JA, Ohori M, **Kattan MW**, Wheeler T, Maru N, Slawin K, Scardino P. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. *J Urol*. 2008 May;179(S Suppl):S47-S51.
265. Shariat KS, Karakiewicz PI, Margulis V, **Kattan MW**. Inventory of prostate cancer predictive tools. *Curr Opin Urol*. 2008 May;18(3):279-296.
266. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantaoff PW, **Kattan MW**, Lee A, Regan MM, Sartor O: Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. *J Urol*. Jun;179(6):2181-2185.
267. Klein EA, Bianco FJ, Serio AM, Eastham JA, **Kattan MW**, Pontes JE, Vickers AJ, Scardino PT. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. *J Urol*. 2008 Jun;179(6):2212-2216.
268. Eastham JA, Scardino PT, **Kattan MW**. Predicting an optimal outcome after radical prostatectomy: the "Trifecta" nomogram. *J Urol*. 2008 Jun;179(6):2210-2211.
269. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, **Kattan MW**. Pre-operative nomogram predicting 12-year probability of metastatic renal cancer. *J Urol*. 2008 Jun;179(6):2146-2151.
270. Walker E, Hernandez AV, **Kattan MW**. Meta analysis: basics, strengths and limitations. *Cleve Clin J Med*. 2008 Jun; 75(6):431-439.
271. Dong F, **Kattan MW**, Steyerberg EW, Jones JS, Stephenson AJ, Schröder FH, Klein EA. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. *J Urol*. 2008 Jul;180(1):150-154.
272. Hernandez AV, Walker E, Ioannidis JP, **Kattan MW**. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. *Am Heart J*. 2008 Jul;156(1):23-30.
273. Shariat SF, Karakiewicz, PI, Suardi N, **Kattan, MW**. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. *Clin Cancer Res*. 2008 Jul15;14(4):4400-4407.
274. Schröder F, **Kattan MW**. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. *Eur Urol*. 2008 Aug;54(2):274-290.
275. Vickers AJ, Basch E, **Kattan MW**. Against diagnosis. *Ann Intern Med*. 2008 Aug 5;149(3):200-203.
276. Fu AZ, **Kattan MW**. Utilities should not be multiplied: evidence from the preference-based scores in the United States. *Med Care*. 2008 Sep;46(9):984-990.
277. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, **Kattan MW**. Prognostic nomogram for Sunitinib in patients with metastatic renal cell carcinoma. *Cancer*. 2008 Oct 1;113(7):1552-1558.

278. Gross ND, Patel SG, Carvalho AL, Chu PY, Kowalski LP, Boyle JO, Shah JP, **Kattan MW**. Nomogram for deciding adjuvant treatment after surgery for oral cavity squamous cell carcinoma. *Head Neck*. 2008 Oct;30(10):1352-1360.
279. Lane BR, **Kattan MW**. Prognostic models and algorithms in renal cell carcinoma. *Urol Clin N Am*. 2008 Nov;35(4):613-625.
280. Shariat SF, Karakiewicz PI, Roehrborn CG, **Kattan MW**. An updated catalog of prostate cancer predictive tools. *Cancer*. 2008 Dec 1;113(11):3075-3099.
281. Wells B, Jain A, Arrigain S, Yu C, Rosenkrans, Jr W, **Kattan MW**. Predicting six-year mortality risk in patients with type 2 diabetes. *Diabetes Care*. 2008 Dec;31(12):2301-2306.
282. Stone N, Stock R, Potters L, Roach M, Chinohara K, Davis B, Ciezki J, **Kattan MW**, Fearn PA. Multicenter analysis of impact of high biological effective dose (BED) on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated by permanent prostate brachytherapy. *Int J Radiant Oncol Biol Phys*. 2009 Feb 1;73(2):341-346.
283. **Kattan MW**, Vickers AJ, Yu C, Bianco FJ, Cronin AM, Eastham JA, Klein EA, Reuther AM, Pontes JE, Scardino PT. Preoperative and postoperative nomograms incorporating surgeon experience for localized prostate cancer. *Cancer*. 2009 March 1;115(5):1005-1010.
284. Tiong HY, Goldfarb DA, **Kattan MW**, Alster JM, Thuita L, Yu C, Wee A, Poggio ED. Nomograms for predicting graft function and survival in living donor kidney transplantation based on the UNOS Registry. *J Urol*. 2009 Mar;181(3):1248-1255.
285. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham JA, Møller H, **Kattan MW**, Gerald W, Cooper C, Scardino PT, Cuzick J. Ki-67 and outcome in clinically localized prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. *Br J Cancer*. 2009 Mar 24;100(6):888-893.
286. Ficarra V, Novara G, Boscolo-Berto R, Artibani W, **Kattan MW**. How accurate are present risk group assignment tools in penile cancer? *World J Urol*. 2009 Apr;27(2):155-160.
287. Kelloff GJ, Choyke P, Coffey DS, **Prostate Cancer Imaging Working Group**. Challenges in clinical prostate cancer: role of imaging. *AJR Am J Roentgenol*. 2009 Jun;192(6):1455-1470.
288. Pantalone KM, **Kattan MW**, Yu C, Wells, BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, metformin, or sulfonylureas. A retrospective analysis. *Acta Diabetol*. 2009 Jun;46(2):145-154.
289. Nguyen CT, **Kattan MW**. Development of a prostate cancer metagram: a solution to the dilemma of which prediction tool to use in patient counseling. *Cancer*. 2009 Jul 1;115(13 Suppl):3039-3045.
290. Nguyen CT, Zelefsky MJ, **Kattan MW**. The current state of brachytherapy nomograms for patients with clinically localized prostate cancer. *Cancer*. 2009 Jul 1;115(13 Suppl):3121-3127.
291. Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham JA, Møller H, **Kattan MW**, Cooper CS, Scardino PT, Cuzick J, Berney DM. p53 immunohistochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. *BJU Int*. 2009 Jul;104(1):20-24.

292. Fuchsjäger MH, Shukla-Dave A, Hricak H, Wang L, Touijer K, Donohue JF, Eastham JA, **Kattan MW**. Magnetic resonance imaging in the prediction of biochemical recurrence after radical prostatectomy. *BJU Intl*. 2009 Aug;104(3):315-320.
293. Stephenson AJ, **Kattan MW**, Eastham JA, Bianco Jr. FJ, Yossepowitch O, Vickers AJ, Klein E, Wood P, Scardino PT. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. *J Clin Oncol*. 2009 Sep 10;27(26):4300-4305.
294. Stephenson AJ, Wood DP, **Kattan MW**, Klein EA, Scardino PT, Eastham JA, Carver BS. Location, extent, and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy compared to their presence or absence. *J Urol*. 2009 Oct;182(4):1357-1363.
295. Slovin SF, Kelly WK, Wilton A, **Kattan MW**, Myskowski P, Mendelsohn J, Scher HI. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer*. 2009 Oct;7(3):E77-E82.
296. **Kattan MW**. Comparative effectiveness: a table of expected benefits and harms. *Med Decis Making*. 2009 Nov-Dec;29(6):NP3-NP5.
297. Reddy SK, **Kattan MW**, Yu C, Ceppa EP, de la Fuente SG, Fong Y, Clary BM, White RR. Evaluation of peri-operative chemotherapy using a prognostic nomogram for survival after resection of colorectal liver metastases. *HPB (Oxford)*. 2009 Nov;11(7):592-599.
298. Vickers AJ, Cronin AM, **Kattan MW**, Gönen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH, International Bladder Cancer Nomogram Consortium. Clinical benefits of a multivariable prediction model for bladder cancer: a decision analytic approach. *Cancer*. 2009 Dec 1;115(23):5460-5469.
299. Shariat SF, **Kattan MW**, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. *Future Oncol*. 2009 Dec;5(10):1555-1584.
300. Eskicorpaci SY, Türkeri L, Karabulut E, Cal C, Akpınar H, Baltacı S, Baykal K, the Turkish Validation Study Group of Kattan Preoperative Nomogram, **Kattan MW**, Ozen H. Validation of two preoperative Kattan Nomograms predicting recurrence after radical prostatectomy for localized prostate cancer in Turkey: a multicenter study of the Uro-Oncology Society. 2009 Dec;74(6):1289-1295.
301. **Kattan MW**. Evaluating a marker's contribution to a nomogram: the GEMCaP example. *Clin Cancer Res*. 2010 Jan 1;16(1):1-3.
302. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, **Kattan MW**, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. *Crit Rev Oncol Hematol*. 2010 Jan 1;28(1):119-125.
303. Nguyen CT, Fu AZ, Gilligan TD, Wells BJ, Klein EA, **Kattan MW**, Stephenson AJ. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. *J Clin Oncol*. 2010 Jan;28(1):119-125.

304. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, **Kattan MW**. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010 Jan;21(1):128-138.
305. Nguyen CT, Stephenson AJ, **Kattan MW**. Are nomograms needed in the management of bladder cancer? *Urol Oncol*. 2010 Jan-Feb;28(1):102-107.
306. Moussa AS, **Kattan MW**, Berglund R, Yu C, Fareed K, Jones JS. A nomogram for predicting upgrading in patients with low and intermediate grade prostate cancer in the era of extending prostate sampling. *BJU Int*. 2010 Feb;105(3):352-358.
307. Nguyen CT, Yu C, Moussa A, **Kattan MW**, Jones SJ. Performance of the prostate cancer prevention trial risk calculator in a contemporary cohort of men screened for prostate cancer and diagnosed with extended prostate biopsy schemes. *J. Urol*. 2010 Feb;183(2):529-533.
308. **Kattan MW**, Marasco J. What is a real nomogram? *Semin Oncol*. 2010 Feb;37(1): 23-26.
309. Satake N, Ohori M, Yu C, **Kattan MW**, Ohno Y, Miyakawa A, Hatano T, Tachibana M. Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens. *Int J Urol*. 2010 March;17(3):267-272.
310. Vickers AJ, Cronin AM, **Kattan MW**, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH and The International Bladder Cancer Nomogram Consortium. Why can't nomograms be more like Netflix? *J Urol*. 2010 Mar;75(3):511-513.
311. Potters L, Stone N, Stock R, Davis B, Fearn P, Ciezki J, **Kattan MW**, Roach M, Zelefsky M. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. *Int J Radiat Oncol Biol Phys*. 2010 Mar 15;76(4):1061-1065.
312. Fu AZ, Cantor SB, **Kattan MW**. Use of nomograms for personalized decision-analytic recommendations. *Med Decis Making*. 2010 Mar/Apr;30(2):267-274.
313. Vickers AJ, Bianco FJ, Cronin AM, Eastham JA, Klein EA, **Kattan MW**, Scardino PT. The learning curve for surgical margins after open radical prostatectomy: implications for the use of margin status as an oncologic endpoint. *J Urol*. 2010 Apr;183(4):1360-1365.
314. Katz M, Efstathiou J, D'Amico AV, **Kattan MW**, Sanda M, Nguyen P, Smith MR, Zietman AL, Carroll PR. CaP calculator: an online decision support tool for clinically localized prostate cancer. *BJU Int*. 2010 May;105(10):1417-1422.
315. Earnshaw SR, McDade CL, Black LK, Bell CF, **Kattan MW**. Cost-effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. *Pharmacoeconomics*. 2010 Jun;28(6):489-505.
316. Ohori M, **Kattan MW**, Yu C, Matsumoto K, Satoh T, Ishii J, Miyakawa A, Irie A, Iwamura M, Tachibana M. Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy. *Int J Urol*. 2010 Jun;17(6):534-540.

317. Pantalone K, **Kattan MW**, Yu C, Wells B, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman R. The risk of overall mortality in patients with Type 2 Diabetes receiving different combinations of sulfonylureas and metformin. A retrospective analysis. *Diabetic Med.* 2010 Jun;33(6):1224-1229.
318. Shoskes DA, Nickel JC, **Kattan MW**. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. *Urology.* 2010 Jun;75(6):1249-1253.
319. Schroeck FR, **Kattan MW**, Moul JW, Aronson WJ, Presti Jr JC, Terris MK, Kane CJ, Amling CL, Sun L, Freedland SJ. Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy (RP). *BJU Int.* 2010 Jun;105(12):1654-1659.
320. Dalton JE, **Kattan MW**. Recent advances in evaluating the prognostic value of a marker. *Scand J Clin Lab Invest Suppl.* 2010 Jul;242:59-62.
321. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, **Kattan MW**, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN. Management of prostate cancer in senior adults: recommendations of a working group of the International Society of Geriatric Oncology (SIOG). *BJU Int.* 2010 Aug;106(4):462-469.
322. Donohue TR, **Kattan MW**, Nelson SD, Tap WD, Eilber FR, Eilber FC. Evaluation of neoadjuvant therapy and histopathologic response in primary, high grade retroperitoneal sarcomas using the sarcoma nomogram. *Cancer.* 2010 Aug 15;116(16):3883-3891.
323. Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones SJ, **Kattan MW**, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schroder FH, Lilja H. The relationship between prostate-specific antigen and prostate cancer risk: the prostate biopsy collaborative group. *Clin Caner Res.* 2010 Sept 1;16(17):4374-4381.
324. Barsoum WK, Murray TG, Klika AK, Green K, Miniaci SL, Wells BJ, **Kattan MW**. Predicting patient discharge disposition following total joint Arthroplasty in the United States. *J Arthroplasty.* 2010 Sept;25(6):885-892.
325. Talantov D, Jatkoa TA, Bohn M, Zhang Y, Ferguson AM, Stricker PD, **Kattan MW**, Sutherland RL, Kench JG, Wang W, Henshall SM. Gene-based prediction of progression for clinically localized prostate cancer patients following radical prostatectomy. *J Urol.* 2010 Oct;184(4):1521-1528.
326. Schold JD, Srinivas TR, Poggio ED, Stephany BR, Flechner SM, Goldfarb DA, **Kattan MW**. Hidden selection bias deriving from donor organ characteristics does not affect performance evaluations of kidney transplant centers. *Med Care.* 2010 Oct;48(10):907-914.
327. Kudahetti SC, Fisher G, Ambroisine L, Prowe D, **Kattan MW**, Foster CS, Moller H, Oliver T, Fletcher A, Cooper C, Reuter VE, Scardino PT, Cuzick J, Berney DM. Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localized prostate cancer. *Pathology.* 2010 Oct;42(6):519-523.
328. Ingram DG, **Kattan MW**. Risk grouping vs. risk continuum for patients with clinically localized prostate cancer: a taxometric test. *J. Urol.* 2010 Nov;184(5):1937-1941.

329. Lee MC, Moussa AS, Yu C, **Kattan MW**, Magi-Galluzzi C, Jones JS.. Multifocal high-grade prostatic intraepithelial neoplasia is a risk factor for subsequent development of prostate cancer. *J. Urol.* 2010 Nov;184(5):1958-1962.
330. Moussa AS, **Kattan MW**, Yu C, Jones SJ. Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling. *BJU Int.* 2010 Nov;106(9):1309-1314.
331. Rajab R, Fisher G, **Kattan MW**, Foster CS, Oliver T, Møller H, Reuter V, Scardino P, Cuzick J, Berney DM; on behalf of the Transatlantic Prostate Group. Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort. *Virchows Arch.* 2010 Nov;457(5):547-553.
332. Lughezzani G, Briganti A, Karakiewicz PI, **Kattan MW**, Montorsi F, Shariat SF, Vickers AJ. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. *Eur Urol.* 2010 Nov;58(5):687-700.
333. Nixon IJ, Ganly I, Hann LE, Lin O, Yu C, Brandt S, Shah JP, Shaha A, **Kattan MW**, Patel SG. Nomogram for predicting malignancy in thyroid nodules using clinical, biochemical, ultrasonographic, and cytologic features. *Surgery.* 2010 Dec;148(6):1120-1128.
334. Pickels T, Yu C, **Kattan MW**. Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. *Brachytherapy.* 2011 Jan-Feb;10(1):9-14.
335. Rajab R, Fisher G, **Kattan MW**, Foster CS, Møller H, Oliver T, Reuter V, Scardino PT, Cuzick J, Berney DM. An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent. *Mod Pathol.* 2011 Jan;24(1):58-63.
336. Major JM, Klonoff-Cohen HS, Pierce JP, Slymen DJ, Saltzstein SL, Macera CA, Mercola D, **Kattan MW**. Prostate cancer postoperative nomogram scores and obesity. *PLoS One.* 2011 Feb 24;6(2):e17382.
337. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, **Kattan MW**, Yu C, Klein EA, Stephenson AJ. Predicting fifteen-year prostate cancer-specific mortality following radical prostatectomy. *J Urol.* 2011 Mar;185(3):869-875.
338. **Kattan MW**, Yu C, Salomon L, Vora K, Touijer K, Guillonneau B. Development and validation of a preoperative nomogram for disease recurrence within 5 years following laproscopic radical prostatectomy for prostate cancer. *Urology.* 2011 Feb;77(2):396-401.
339. Vickers AJ, Fearn P, Guillonneau B, Scardino PT, **Kattan MW**, Klein EA. Surgery confounds biology: the predictive value of stage, grade and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience. *Int J Cancer.* 2011 Apr 1;128(7):1697-1702.
340. Swanson GP, Yu C, **Kattan MW**, Hermans MR. Validation of postoperative nomograms in prostate cancer. *Urology.* 2011 Jul;78(1):105-109.
341. Choi I, Wells BJ, Yu C, **Kattan MW**. An empirical approach to model selection through validation for censored survival data. *J Biomed Inform.* 2011 Aug;44(4):595-606.

342. Nam RK, **Kattan MW**, Chin JL, Trachtenberg J, Singal R, Rendon R, Klotz LH, Sugar L, Sherman C, Izawa J, Bell D, Stanimirovic A, Venkateswaran V, Diamandis E, Yu C, Loblaw DA, Narod SA. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. *J Clin Oncol*. 2011 Aug 1;29(22):2959-2964.
343. Zaytoun OM, **Kattan MW**, Moussa AS, Li J, Jones SJ. Development of an improved nomogram for prediction of the outcome of the initial prostate biopsy based on readily available clinical information. *Urology*. 2011 Aug;78(2):392-398.
344. **Kattan MW**, Earnshaw SR, McDade CL, Black LK, Andriole GL. Cost-effectiveness of chemoprevention for prostate cancer with Dutasteride in a high risk population based on results from the REDUCE clinical trial. *Appl Health Econ Health Policy*. 2011 Sept1;9(5):305-315.
345. Ali S, Yu C, Palmer FL, Ganly I, Shaha A, Shah JP, **Kattan MW**, Patel SG. Nomogram to aid selection of patients for short-stay thyroidectomy based on risk of postoperative hypocalcemia. *Arch Otolaryngol Head Neck Surg*. 2011 Nov;137(11):1154-1160.
346. **Kattan MW**, Gerds, TA. Making and evaluating a statistical prediction model for the absolute risk of prostate cancer recurrent. *Cancer*. 2011 Nov 15;117(22):5026-5028.
347. Ali S, Yu C, Palmer FL, Ganly I, Shaha A, Shah JP, **Kattan MW**, Patel SG. Nomogram to aid selection of patients for short-stay thyroidectomy based on risk of postoperative hypocalcemia. *Arch Otolaryngol Head Neck Surg*. 2011 Nov;137(11):1154-1160.
348. Tamblyn D, Yu C, **Kattan MW**, Pinnock C, Kopsaftis T. USANZ: comparative analysis of three risk assessment tools in Australian prostate cancer patients. *BJU Int*. 2011 Nov;108 Suppl 2:51-56.
349. Weiser MR, Gönen M, Chou JF, **Kattan MW**, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. *J Clin Oncol*. 2011 Dec 20;29(36):4796-4802.
350. Nam RK, Zhang W, Siminovitch K, Shlien A, **Kattan MW**, Klotz LH, Tachtenbert J, Lu Y, Zhang J, Yu C, Toi A, Loblaw DA, Venkateswaran V, Stanimirovic A, Sugar L, Malkin D, Seth A, Narod SA. New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. *Cancer Biol Ther*. 2011 Dec 1;12(11):997-1004.
351. Weiser MR, Gönen, Chou JF, **Kattan MW**, Schrag D. Predicting survival following curative colectomy for cancer: individualizing colon cancer staging. *J Clin Oncol*. 2011 Dec 20;29(36):4796-4802.
352. Fenig DM, **Kattan MW**, Mills JN, Gisbert M, Yu C, Lipshultz LI. Nomogram to preoperatively predict the probability of requiring an epididymovasostomy during a vasectomy reversal. *J Urol*. 2012 Jan;187(1):215-218.
353. Steyerberg EW, Pencina MJ, Lingsma HF, **Kattan MW**, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. *Eur J Clin Invest*. 2012 Feb;42(2):216-228.

354. Valdagni R, **Kattan MW**, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E, Gabriele P, Mauro FA, Baccolini M, Bianci C, Menegotti L, Monti AF, Stasi M, Giganti MO, Fiorino C. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. *Int J Radiat Oncol Biol Phys.* (In Press).
355. Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian K, Udo K, Scardino P, Eastham J, **Kattan MW**. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. *BJU Int.* (In Press).
356. Hsiao W, Rosoff JS, Piccorelli A, **Kattan MW**, Greenwood EA, Mulhall JP, Goldstein M. Nomograms to predict durable patency after microsurgical vasectomy reversal. *J Urol.* (In Press).
357. Nguyen P, Chen MH, Hoffman K, Chen R, Hu J, Bennett C, **Kattan MW**, Sartor O, Stein K, D'Amico A. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. *BJU Int.* (In Press).
358. Shen B, Yu C, Lian L, Remzi FH, Kiran RP, Fazio VW, **Kattan MW**. Prediction of late-onset pouch failure in patients with restorative proctocolectomy with a nomogram. *J. Crohns Colitis.* (In Press).
359. Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JJ, Haslag-Minoff J, Deasy JO, Michalski JM, Kallogjeri D, Piccirillo JF, Rabah DM, Yu C, **Kattan MW**, Stephenson AJ. Survival among men with clinically localized prostate cancer treated by radical prostatectomy or radiation therapy in the prostate-specific antigen era. *J Urol.* (In Press).
360. Hakimi AA, Agalliu I, Ho AY, Ghavamian R, Yu C, **Kattan MW**, Rabbani F. The role of age, race and PSA velocity in detection of prostate cancer overall and high grade cancer in men with multiple PSAs before biopsy in an ethnically diverse, disadvantaged population. *J Urol.* (In Press).
361. Marko N, Xu Z, Gao T, **Kattan MW**, Weil R. Predicting survival in women with breast cancer and brain metastasis: a nomogram outperforms current survival prediction models. *Cancer.* (In Press).
362. Bevilacqua JLB, **Kattan MW**, Yu C, Koifman S, Mattos IE, Koifman RJ, Bergmann A. Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer. *Ann Surg Oncol.* (In Press).
363. Ankerst DP, Boeck A, Freedland SJ, Thompson IM, Cronin AM, Roobol MJ, Hugosson J, Jones SJ, **Kattan MW**, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Bartsch G, Klocker H, Horninger W, Benhikh A, Salama G, Villers A, Moreira DM, Schroder FH, Lilja H, Vickers AJ. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. *World J Urol.* (In Press).
364. Ortega EMM, Cordeiro GM, **Kattan MW**. The log-geta weibull regression model with application to predict recurrence of prostate cancer. *Stat Pap.* (In Press).
365. Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, **Kattan MW**, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers, Transatlantic Consensus Group. Transatlantic consensus group on active surveillance and focal therapy for prostate cancer. *BJU Int.* (In Press).

366. Roobol MJ, Schröder FH, Hugosson J, Jones SJ, **Kattan MW**, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horniger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the Prostate Biopsy Collaborative Group. *World J Urol.* (In Press).
367. Ortega EMM, Cordeiro GM, **Kattan MW**. The negative binomial-beta weibull regression model to predict cure of prostate cancer. *J Appl Stat.* (In Press).
368. Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, Sonoda Y, Abu-Tustum NR, Huh J, Barakat RR, **Kattan MW**, Chi DS. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. *Gynecol Oncol.* (In Press).
369. Schold JD, Buccini LD, **Kattan MW**, Goldfarb DA, Flechner SM, Srinivas TR, Poggio ED, Fatica R, Kayler LK, Sehgal AR. The association of community health indicators with outcomes for kidney transplant recipients in the United States. *Arch Surg-Chicago.* (In Press).
370. **Kattan MW**, Potters L. Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy. *BJU Int.* (In Press).

#### **Reviews, Chapters, and Editorials:**

1. **Kattan MW**. Inductive expert systems versus human experts. *Artif Intell Exp* 1994; 9(4):32-38.
2. **Kattan MW**, Beck JR. Artificial neural networks for medical classification decisions. *Arch Pathol Lab Med* 1995; 119:672-677.
3. Beck JR, **Kattan MW**, Miles BJ. Quantitative approaches to diagnostic testing and decision making in genitourinary oncology. In Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS, eds. *Comprehensive Textbook of Genitourinary Oncology*. Baltimore: Williams and Wilkins, 1995:21-32.
4. **Kattan MW**, Cowen ME, Miles BJ. Computer modeling in urology. *Urology* 1996; 47(1):14-21.
5. **Kattan MW**, Ishida H, Scardino PT, Beck JR. Applying a neural network to prostate cancer survival data. In Lavra N, Karavnou E, Zupan B, eds. *Intelligent Data Analysis in Medicine and Pharmacology*. Boston: Kluwer Academic, 1997:295-306.
6. Scardino PT, Wheeler TM, **Kattan MW**. Is cure of prostate cancer possible in those for whom it is necessary? In Kurth KH, Mickisch GH and Schoder FH, eds. *Renal Bladder and Prostate Cancer: An Update*. New York:Parthenon, 1999:131-137.
7. **Kattan MW**, Miles BJ. The patient's choice of surgery for clinically localized prostate cancer. In Vaughan Jr. ED and Perlmutter AP, eds. *Atlas of Clinical Urology*. London: Churchill Livingstone, 1999:9.1-9.7.
8. **Kattan MW**, Beck JR, Miles BJ. Quantitative approaches to diagnostic testing and decision making in genitourinary oncology. In Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS, eds. *Comprehensive Textbook of Genitourinary Oncology*. Philadelphia: Lippincott Williams and Wilkins, 2000:22-32.

9. D'Amico AV, Moul J, **Kattan MW**. Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific antigen level, race, molecular markers, and neural networks. In Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS, eds. *Comprehensive Textbook of Genitourinary Oncology*. Philadelphia: Lippincott Williams and Wilkins, 2000:680-700.
10. Slawin KM, **Kattan MW**, Scher HI, Scardino PT. Prostate-specific antigen in screening, prognosis of the primary tumor and monitoring of recurrent disease. In Perry MC, ed. *2000 Spring Educational Book*. Alexandria: ASCO, 2000:596-608.
11. **Kattan MW**. Expert Systems in Medicine. In: Smelser NJ, Baltes PB, eds. *International Encyclopedia of the Social & Behavioral Sciences*. Pergamon: Oxford; 2001:5135-5139.
12. **Kattan MW**. Statistical prediction models, artificial neural networks, and the sophism "I am a patient not a statistic". *J Clin Oncol* 2002;20:885-887.
13. Slawin KM, Canto EI, Shariat SF, Gore JL, Kim E, **Kattan MW**, Wheeler TM, Nath RK. Sural nerve interposition grafting during radical prostatectomy. *Rev Urol*. 2002 Winter;4(1):17-23.
14. **Kattan MW**, Introduction. *Seminars in Urologic Oncology* 2002;20(2):79.
15. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani P, Scardino PT, **Kattan MW**. Comparisons of nomograms and urologists' predictions in prostate cancer. *Seminars in Urologic Oncology* 2002;20(2):82-88.
16. Eastham JA, **Kattan MW**, Scardino PT. Nomograms as predictive models. *Seminars in Urologic Oncology* 2002;20(2):108-115.
17. **Kattan MW**. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. *Curr Opin Urol* 2003;13(2):111-6.
18. **Kattan MW**. Judging new markers by their ability to improve predictive accuracy. *J Natl Cancer Inst*. 2003;95:634-635.
19. Swindle PW, **Kattan MW**, Scardino PT. Markers and meaning of primary treatment failure of carcinoma of the prostate. *Urol Clin N Am* 30: 377-401, 2003.
20. Yossepowitch O, Trabulsi EJ, **Kattan MW**, Scardino, PT: Predictive factors in prostate cancer: implications for decision making. *Cancer Invest* 2003;21(3): 465-80.
21. Cho D, Di Blasio C, Rhee AC, and **Kattan MW**. Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). *Urol Oncol: Seminars and Original Investigations* 2003 Jul-Aug;21(4):282-91.
22. **Kattan, MW**. Better predictions for patients. *Family Urology* 2003; 8(3): 11-15.
23. Di Blasio CJ, Rhee AC, Cho D, Scardino PT and **Kattan MW**. Predicting clinical endpoints: treatment nomograms in prostate cancer. *Seminars in Oncology* 2003: 231-252.

24. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, **Kattan MW**, Nanus DM, Nelson JB, Oh W, Roach III M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: Prevention, Detection, and Treatment. *J Urol* 2003; 170: S3-S5.
25. Resnick MI, Gospodarowicz M, Gibod LB, Bono A, Brawer M, Elhilai M, **Kattan MW**, Lilja H, Murai M, O'Sullivan B, Turkes A, and Wein A: Markers and Prognostic Factors. In: Denis L, Bartsch G, Khoury S, Murai M, and Partin A (eds). *Prostate Cancer*. Health Publications: Paris; 2003. 49-89.
26. **Kattan MW**, Miles BJ. Decision making for clinically localized prostate cancer. *Atlas of the prostate*, 2<sup>nd</sup> Ed. Edited by Bruskewitz RC. Current Medicine, Inc. 2003;115-122.
27. Trabulsi EJ, Scardino PT, **Kattan MW**: The decision-making process for prostate cancer. In: Mydlo JH and Godec CJ (eds). *Prostate Cancer: Science and clinical practice*. Academic Press: Amsterdam, San Diego; 2004: 232-252.
28. Stephenson AJ, **Kattan MW**. Stratification of risk for disease progression following initial therapy for prostate cancer: nomograms do it better. *New Urology: Prostate Cancer* 2004; 1(3): 1-9.
29. Ohori M, **Kattan MW**, Scardino PT, Wheeler TM. Radical prostatectomy for carcinoma of the prostate. *Mod Pathol*. 2004 Mar;17(3):349-359.
30. Shariat SF, Canto EL, **Kattan MW**, Slawin KM. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. *Rev Urol*. 2004 Spring;6(2):58-72.
31. Porter CR, **Kattan M**. Predictive modeling in treatment outcomes for prostate cancer: Tools for the urologist. *AUA Update Series*, 2004 (CD).
32. Stephenson AJ, **Kattan MW**. Utility of outcome prediction models for prostate cancer therapy. *Comprehensive Textbook of Genitourinary Oncology*, 3<sup>rd</sup> Ed. Edited by Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS. Philadelphia: Lippincott, Williams, and Wilkins, 2005.
33. Slawin KM, **Kattan MW**. The use of nomograms for selecting BPH candidates for dutasteride therapy. *Rev Urol*.2004; 6(suppl 9):S40-S45.
34. Slawin KM, Diblasio CJ, **Kattan MW**. Minimally invasive therapy for prostate cancer: use of nomograms to counsel patients about the choice and probably outcome of therapy. *Rev Urol*. 2004;6 Suppl 4:S3-S8.
35. Lane BR, **Kattan MW**. Predicting outcomes in renal cell carcinoma. *Curr Opin Urol*. 2005 Sep; 15(5):289-297.
36. Katz EM, **Kattan MW**. How to judge a tumor marker. *Nat Clin Pract Oncol*. 2005 Oct;2(19):482-483.
37. **Kattan MW**, Miles BJ. Decision making for clinically localized prostate cancer. *Atlas of the prostate*, 3<sup>rd</sup> Ed. Edited by Scardino PT, Slawin K. Current Medicine Group. 2005 Nov 18.

38. Shipley WU, Scardino PT, Kaufman DS, **Kattan MW**. Advising patients with early prostatic cancer on their treatment decision. *Comprehensive Textbook of Genitourinary Oncology*, 3<sup>rd</sup> Ed. Edited by Vogelzang N, Scardino PT, Shipley WU, Debruyne FMJ, Marston-Linehan W. Philadelphia: Lippincott Williams & Wilkins. 2006: 153-157.
39. Mallah K, **Kattan MW**. Multivariate models for predicting biochemical recurrence after definitive local therapy. *Prostate Cancer: Principles and Practice*, 1<sup>st</sup> Ed. Edited by Kirby R, Partin AW, Feneley M, Parsons JK. London: Taylor Francis. 2006.
40. Hixson ED, **Kattan MW**. Nomograms are more meaningful than severity-adjusted institutional comparisons for reporting outcomes. *Eur Urol*. 2006 Apr;49(4):600-603.
41. Stephenson AJ, **Kattan MW**. Nomograms for prostate cancer. *BJU Int*. 2006 Jul;98(1):39-46.
42. Chun FKH, Karakiewicz PI, Briganti A, Gallina A, **Kattan MW**, Montorsi F, Huland H, Graefen M. Prostate cancer nomograms: an update. *Eur Urol*. 2006 Nov;50(5):914-926
43. **Kattan MW**. Editorial: validating a prognostic model. *Cancer*. 2006 Dec;176(6):2458.
44. **Kattan MW**. Evaluation and assessment of molecular markers and their translation into clinical practice. *Molecular Oncology of Prostate Cancer*. Edited by Ross JS, Foster CS. Jones & Bartlett. 2006.
45. Miller DM, Fu A, **Kattan MW**. The role of health related quality of life assessment in the conduct of evidence-based medicine. *Multiple Sclerosis Therapeutics*, 3<sup>rd</sup> Edition. Edited by Cohen JA, Rudick RA. Informa Healthare. 2007.
46. **Kattan MW**, Gönen M, Scardino PT. The development and execution of medical prediction models. *Outcome Prediction in Cancer / Science in Multidisciplinary series*. Edited by Taktak AFG, Fisher AC. Elsevier. 2007.
47. Van Zee KJ, **Kattan MW**. Validating a predictive model for presence of additional disease in the non-sentinel lymph nodes of a woman with sentinel node positive breast cancer. *Ann Surg Oncol*. 2007 Aug;14(8):2177-2178.
48. **Kattan MW**. Should physicians use the updated Partin tables to predict pathologic stage in patients with prostate cancer? *Nat Clin Pract Urol*. 2007 Nov;4(11):592-593.
49. Babineau DC, **Kattan MW**. Assessment of treatment strategies in prostate cancer using risk stratification and prediction of clinical outcomes. *Therapeutic Strategies in Prostate Cancer*. Edited by Feneley M, Payne H. Clinical Publishing 2007.
50. **Kattan MW**. Updated nomograms to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin Tables) based on cases from 2000 to 2005. *Eur Urol*. 2007 Nov;52(5): 1528.
51. **Kattan MW**, Scardino PT. Evidence for the usefulness of nomograms. *Nat Clin Pract Urol*. 2007 Dec;4(12):638-639.
52. Babineau D, **Kattan MW**. Clinical trials and their principles. *A Handbook of Urological Oncology*. Edited by Nargund VH, Raghavan D, Sandler HM. Springer-Verlag London Limited 2008.

53. Karakiewicz PI, **Kattan MW**. Prostate cancer nomograms and how they measure up to neural networks. Prostate Biopsy: Indications, Techniques, and Complications. Edited by Jones JS. Humana Press 2008.
54. Klein EA, **Kattan MW**, Stephenson A, Vickers A. How many lymphadenectomies does it take to cure one patient? Eur Urol. 2008 Jan;53(1):13-15.
55. **Kattan MW**. Nomograms are difficult to beat. Eur Urol. 2008 Apr;53(4):671-672.
56. **Kattan MW**. Predicting prostate cancer behavior – what is a urologist to do? J Urol. 2008 May;179(5):1658-1659.
57. **Kattan MW**, Gönen M. The prediction philosophy in statistics. Urol Oncol. 2008 May-Jun;26(3):316-319.
58. **Kattan MW**. Do we need more nomograms for predicting outcomes in patients with prostate cancer? Nat Clin Pract Urol. 2008 Jul;5(7):366-367
59. **Kattan MW**. Should I use this nomogram? BJU Int. 2008 Sept;102(4):421-424.
60. Shariat SF, **Kattan MW**. Nomograms for prostate cancer. In: Akerst DP, Tangen CM, Thompson, Jr IM, eds. Prostate cancer Screening. 2<sup>nd</sup> ed. New York, New York, Humana, 2009. Chapter 10: 117-180.
61. Valdagani R, Scardino PT, Denis L, **Kattan MW**. Predictive modeling in prostate cancer: a conference summary. Eur Urol. 2009 Feb;55(2):300-302.
62. Ficarra V, Novara G, Boscolo-Berto R, Artibani W, **Kattan MW**. How accurate are present risk group assignment tools in penile cancer? World J Urol. 2009 Apr;27(2):155-160.
63. **Kattan MW**. Prediction models for transitional cell carcinoma. J. Urol. 2009 Au;182(2):423-424.
64. **Kattan MW**, Jones JS. The ultimate prostate cancer biopsy decision support tool. Eur Urol. 2010 Jan;57(1):9-11.
65. **Kattan MW**. The many uses of cancer prediction tools. Semin Oncol. 2010 Feb;37(1): 20-22.
66. Patrick R, Buccini L, **Kattan MW**. Tailored cancer outcome prediction and informed consent. Semin Oncol. 2010 Feb;37(1): 47-52.
67. **Kattan MW**, Schröder FH, What patients newly diagnosed with clinically localized prostate cancer need to see: an editorial dialogue. Eur Urol. 2010 Aug;58(2):258-260.
68. **Kattan MW**. Classification and regression trees versus nomograms: a bone scan positivity example. Eur Urol. (2010 Apr;57(4):559-561.
69. **Kattan MW**. Comparing prediction tools. Eur Urol. 2010 Apr;57(4):569-570.
70. **Kattan MW**. Factors affecting the accuracy of prediction models limit the comparison of rival prediction models when applied to separate data sets. Eur Urol. 2011 April;59(4):566-567.

71. **Kattan MW**. Doc, what are my chances? A conversation about prognostic uncertainty. *Eur Urol*. 2011 Feb;59(2):224.
72. Jones S, **Kattan MW**. Should decision models drive the decision for prostate biopsy? *Urol Oncol*. 2011 May-Jun;29(3):235-236.
73. Nguyen CT, **Kattan MW**. How to tell if a new marker improves prediction. *Eur Urol*. 2011 Aug;60(2):226-228.

### **Abstracts:**

1. **Kattan MW**, Goto Y, Miles BJ, Ohori M, Scardino PT. Recursive partitioning versus logistic regression in the prediction of clinically important prostate cancer [Abstract]. *Med Dec Making* 1994; 14:434.
2. Inoue Y, Beck JR, **Kattan MW**. A hybrid Markov model for chronic myelogenous leukemia [Abstract]. *Med Dec Making* 1994; 14:433.
3. Dilliogluligil O, Leibman BD, **Kattan MW**, Seale-Hawkins C, Scardino PT. Hazard rates for progression, determined by PSA, after radical prostatectomy for T1-2 prostate cancer [Abstract]. 90th Annual Meeting of the American Urological Association, Las Vegas, Nevada. *J Urol* 1995; 153:391A.
4. Goto Y, Ohori M, Arakawa A, **Kattan MW**, Scardino PT. Which preoperative factors predict microscopic seminal vesicle invasion or pelvic lymph node metastasis? [Abstract]. 90th Annual Meeting of the American Urological Association, Las Vegas, Nevada. *J Urol* 1995; 153:297A.
5. **Kattan MW**, Miles BJ, Beck JR, Scardino PT. Reexamination of the decision analysis for clinically localized prostatic cancer: Age and grade comparisons [Abstract]. 90th Annual Meeting of the American Urological Association, Las Vegas, Nevada. *J Urol* 1995; 153:390A.
6. Lerner SP, Linn D, Chakraborty S, Truong L, Xu H-J, Wheeler TM, **Kattan MW**, Benedict WF. Correlation of p53 and retinoblastoma protein expression with established pathologic prognostic features in radical cystectomy specimens [Abstract]. 90th Annual Meeting of the American Urological Association, Las Vegas, Nevada. *J Urol* 1995; 153:363A.
7. Song S, Ohori M, **Kattan MW**, Wheeler TM, Berkman S, Scardino PT. Has there been a recent shift towards earlier stage cancer among patients treated with radical prostatectomy? [Abstract]. 90th Annual Meeting of the American Urological Association, Las Vegas, Nevada. *J Urol* 1995; 153:428A.
8. Zbell PJ, **Kattan MW**, Lipshultz LI, Lamb DJ, Coburn M. Semen leukocytes and immature germ cells: Their relationship to each other and to bulk semen parameters [Abstract]. 90th Annual Meeting of the American Urological Association, Las Vegas, Nevada. *J Urol* 1995; 153:428A.
9. **Kattan MW**, Eastham JA, Yawn DH, Scardino PT. A decision analysis of the cost-effectiveness of preoperative autologous blood donation prior to radical retropubic prostatectomy for clinically localized prostate cancer [Abstract]. *Med Decis Making* 1995; 15:429.

10. **Kattan MW**, Miles BJ, Beck JR, Scardino PT. Second order Monte Carlo simulation in the decision to treat clinically localized prostate cancer [Abstract]. *Med Decis Making* 1995; 15:429.
11. Cowen ME, Cahill D, **Kattan MW**, Miles BJ. The value or utility of prostate cancer stages [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:376A.
12. Slawin K, O'Hara M, Song W, Gottenger E, Wang D, Veltri RW, Lebovitz R, **Kattan MW**. Comparison of results obtained using different RT-PCR-PSA assay methods on a single set of clinical specimens [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:417A.
13. **Kattan MW**, Stapleton AMF, Scardino PT. Analysis of a nomogram for predicting final pathological stage of clinically localized prostate cancer [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:421A.
14. Marley GM, Patton KP, Miller MG, Zhao G, Veltri RW, **Kattan MW**, Wright GR, Schellhammer PF, Vessella RL. Free/total prostate specific antigen (PSA) serum ratio predicts probability of cancer diagnosis in patients with elevated total PSA [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:422A.
15. Rogers E, Gurpinar T, Dilliogluligil O, **Kattan MW**, Goad JR, Seale-Hawkins C, Carlton CE Jr, Scardino PT, Griffith DP. The role of digital rectal examination (DRE), biopsy Gleason score and preoperative PSA in selecting patients who require pelvic lymph node dissection for prostate cancer [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:488A.
16. Eastham JA, Truong LD, Rogers E, **Kattan MW**, Flanders KC, Scardino PT, Thompson, TC. Transforming growth factor- $\beta$ 1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:513A.
17. Andenoro J, Madewell L, **Kattan MW**, Wheeler T, Morton RA. Prognostic value of immunohistochemical staining for E-cadherin and a-catenin expression on prostate needle biopsies [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:550A.
18. Dilliogluligil O, Leibman BD, **Kattan MW**, Scardino PT. Comparative long-term outcomes after various management strategies for T1-2 prostate cancer [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:558A.
19. Palapattu GS, Stapleton AMF, Seale-Hawkins C K, **Kattan MW**, Scardino PT. A change in the techniques of radical retropubic prostatectomy markedly improves postoperative potency [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:647A.
20. DeConcini DT, Dilliogluligil O, Stapleton AMF, **Kattan MW**, Scardino PT. Is deferred definitive therapy a reasonable management strategy for clinically localized prostate cancer? [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. *J Urol* 1996; 155:649A.

21. Leibman BD, Dilliogluligil O, Rogers E, **Kattan MW**, Seale-Hawkins C, Wolfinger R, Scardino PT. Analyzing PSA trends in recurrent patients after radical prostatectomy (RP) and radiotherapy (XRT): A novel analysis [Abstract]. 91st Annual Meeting of the American Urological Association, Orlando, Florida. J Urol 1996; 155:698A.
22. Ishida H, **Kattan MW**, Beck JR, Scardino PT. Neural networks do not improve logistic regression models for predicting clinically unimportant prostate cancer [Abstract]. Med Dec Making 1996; 16:459.
23. **Kattan MW**, Stapleton AMF, Wheeler TM, Scardino PT. Discrimination and calibration of published nomogram for prostate cancer [Abstract]. Med Dec Making 1996; 16:459.
24. **Kattan MW**, Cowen ME, Miles BJ, Beck JR. Modeling the impact of comorbidity on the decision to treat clinically localized prostate cancer [Abstract]. Med Dec Making 1996; 16:460.
25. **Kattan MW**, Hess KR, Beck JR, Scardino PT. A comparison between recursive partitioning and the Cox proportional hazards model for prognosis following radical prostatectomy [Abstract]. Med Dec Making 1996; 16:459.
26. Tripp BM, Lin WW, **Kattan MW**, Abrams J, Lamb DJ, Kim ED. Testis biopsy image analysis quantification is highly correlated with FSH levels in infertile men [Abstract]. Fertil Steril 1997; 68 (supp 1):S114.
27. Boone TB, Kim YH, **Kattan MW**. The correlation of urodynamic findings with cranial MRI findings in multiple sclerosis [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:189A.
28. Boone TB, Kim YH, **Kattan MW**. A correlation of Valsalva leak point pressures and endoscopic assessment of urethral coaptation with success after transurethral collagen injection for stress urinary incontinence [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:399A.
29. Eastham JA, **Kattan MW**, Stapleton AMF, Scardino PT. Development of a nomogram using clinical (preoperative) factors to predict progression after radical prostatectomy for prostate cancer [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:189A.
30. Herman JR, Leibman N, **Kattan MW**, Lerner SP. Lymph node metastases and radical cystectomy: Outcomes analysis and the impact of chemotherapy on long-term survival [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:375A.
31. **Kattan MW**, Cowen ME, Miles BJ, Beck JR. Modeling the impact of comorbidity on the decision to treat clinically localized prostate cancer [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:288A.
32. Kim YH, **Kattan MW**, Boone TB. Bladder leak point pressure as a determinant of sphincterotomy failure in detrusor-external sphincter dyssynergia [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:186A.

33. Littrup P, Cowen M, Kattan M, Powell I, Sakr W. Racial differences in the volumes of Gleason score components: The potential for mathematical modeling of mortality differences and screening impact [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:65A.
34. Miles BJ, **Kattan MW**, Scardino PT, Wheeler TM, deVere White RW, Gandour-Edwards R, Humphrey PA, Hudson MLA, Fradet Y, Mahran HE, Bostwick DG. Optimized microvessel density is associated with recurrence [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:297A.
35. Mootha RK, Muezzinoglu B, **Kattan MW**, Wheeler TM, Lerner SP. Transitional cell carcinoma of the prostate in radical cystectomy specimens [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:382A.
36. Palapattu GS, **Kattan MW**, Scardino PT, Wheeler TM. The association of selected pathologic features with prostate cancer (PCa) in a single needle biopsy [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:120A.
37. Partin AW, Chang EG, Walsh PC, Wojno KJ, Oesterling JE, **Kattan MW**, Scardino PT, Pearson JD. Combination of PSA, clinical stage and Gleason score to predict pathological stage: A multi-institutional update 1996 [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:93A.
38. Slawin KM, **Kattan MW**, Wheeler TM, Pham J, Scardino PT. Free/total PSA ratio is not associated with advanced pathologic stage or zone of cancer origin in radical prostatectomy patients [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:115A.
39. Slawin KM, Song W, Gottenger E, Andenoro J, Lebovitz R, Wheeler TM, **Kattan MW**. Preoperative RT-PCR assay for PSA mRNA fails to predict an increased risk of PSA progression in men undergoing radical prostatectomy [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:115A.
40. Smith CP, Kim YH, **Kattan MW**, Priebe M, Boone TB. Effect of Ditropan on bladder compliance and renal damage in spinal cord injured patients with indwelling catheters [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:81A.
41. Stapleton AMF, Zbell P, **Kattan MW**, Yang G, Wheeler TM, Scardino PT, Thompson TC. Assessment of the biological markers p53, KI-67, and apoptotic index as predictive indicators of prostate cancer recurrence following surgery [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:347A.
42. Stapleton AMF, **Kattan MW**, Eastham JA, Wheeler TM, Scardino PT. Which factors best predict treatment failure after radical prostatectomy (RP) for clinically localized prostate cancer? [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. J Urol 1997; 157:391A.

43. Sutton MA, Freund CTM, Berkman SA, Chen S-H, Block A, Dang T, **Kattan MW**, Wheeler TM, Finegold M, Rowley DR, Woo SLC, Lerner SP. The treatment of orthotopic murine bladder tumors with adenovirus-mediated suicide gene therapy [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. *J Urol* 1997; 157:306A.
44. Suyama K, Soh S, Arakawa A, **Kattan MW**, Wheeler TM, Scardino PT. Systematic biopsy results predict seminal vesicle invasion (SVI) better than clinical stage, grade and PSA in T1-3a prostate cancer [Abstract]. 92nd Annual Meeting of the American Urological Association, New Orleans, Louisiana. *J Urol* 1997; 157:298A.
45. **Kattan MW**, Fearn PA, Cowen ME, Miles BJ, Slawin KM, Beck JR. A counter-intuitive result with the adjusted time trade-off [Abstract]. *Med Dec Making* 1997; 17(4):522.
46. **Kattan MW**, Hu J, Cowen ME, Fearn PA, Giesler RB, Miles BJ, Slawin KM, Beck JR. Do easier utility assessment methods work? Comparisons of traditional approaches with phone interviews and the SF-12 [Abstract]. *Med Dec Making* 1997; 17(4):537.
47. **Kattan MW**, Cowen ME, Miles BJ, Beck JR. All patients are not average: Quantification of the danger of applying published decision analysis to the individual patient [Abstract]. *Med Dec Making* 1997; 17(4):542.
48. **Kattan MW**, Wheeler TM, Scardino PT. A nomogram which uses postoperative factors to predict PSA progression after radical prostatectomy for clinically localized prostate cancer [Abstract]. 93rd Annual Meeting of the American Urological Association, San Diego, CA. *J Urol* 1998; 159:182.
49. Abbas F, **Kattan MW**, Wheeler TM, Adler HL, Scardino PT. Survival and cancer control for patients with cT1-T2 prostate cancer with intent to treat by radical prostatectomy [Abstract]. 93rd Annual Meeting of the American Urological Association, San Diego, CA. *J Urol* 1998; 159:252.
50. Miles BJ, Fearn PA, Hu JC, Cowen ME, Giesler RB, **Kattan MW**. Current health utility of newly diagnosed prostate cancer patients [Abstract]. 93rd Annual Meeting of the American Urological Association, San Diego, CA. *J Urol* 1998; 159:258.
51. Nguyen CV, Song W, Scardino PT, Wheeler TM, **Kattan MW**, Slawin KM. RT-PCR for PSA and hK2: implications for staging and patient management in men undergoing radical prostatectomy [Abstract]. 93rd Annual Meeting of the American Urological Association, San Diego, CA. *J Urol* 1998;159:289.
52. Ewton AA, **Kattan MW**, Shimura S, Suyama K, Slawin KM, Scardino PT, Wheeler TM. Clinical and pathological interrelationships between nodular hyperplasia and prostate cancer [Abstract]. 87th Annual Meeting of the United States and Canadian Academy of Pathology, Boston, MA. *Mod Path* 1998; 11(1):82A.
53. Herman CM, Wilcox GE, **Kattan MW**, Scardino PT, Wheeler TM. Microvascular invasion as a predictor of disease progression in prostate cancer [Abstract]. 87th Annual Meeting of the United States and Canadian Academy of Pathology, Boston, MA. *Mod Path* 1998; 11(1):84A.
54. Soh S, Maru N, **Kattan MW**, Scardino PT, Wheeler TM. Pathologic features and prognosis of prostate cancer with seminal vesical involvement [Abstract]. 87th Annual Meeting of the United States and Canadian Academy of Pathology, Boston, MA. *Mod Path* 1998; 11(1):96A.

55. Wilcox GE, **Kattan MW**, Slawin KM, Scardino PT, Wheeler TM. Occult pelvic lymph node (PLN) metastases in patients with “pT3NO” prostate cancer (Pca) [Abstract]. 87th Annual Meeting of the United States and Canadian Academy of Pathology, Boston, MA. Mod Path 1998; 11(1):99A.
56. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, **Kattan MW**, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H. Validation of the Partin tables for predicting pathologic stage of clinically confined prostate cancer [Abstract ]. 94th Annual Meeting of the American Urological Association, Dallas, TX. J Urol 1999; 161(4):238.
57. Slawin KM, Bergamaschi F, Adler H, Nguyen Cuong, Shariat SF, **Kattan MW**, Wheeler TM. Preoperative plasma IGF-1 levels do not correlate with final pathologic stage or progression in patients undergoing radical prostatectomy [Abstract]. 94th Annual Meeting of the American Urological Association, Dallas, TX. J Urol 1999; 161(4):209.
58. Erdamar S, Nguyen C, Shariat S, Wilcox GE, **Kattan MW**, Wheeler TM, Slawin KM. PT3NO Prostate cancer patients with RT-PCR-hK2-L-positive lymph nodes are at higher risk for recurrence [Abstract]. 94th Annual Meeting of the American Urological Association, Dallas, TX. J Urol 1999;161(4):237.
59. **Kattan MW**, Witte M, Morton RA, Cangiano T, deKernion J, Eastham JA, Meyer F, Fradet Y. Validation of a nomogram for predicting disease recurrence following radical prostatectomy for clinically localized prostate cancer [Abstract]. 94th Annual Meeting of the American Urological Association, Dallas, TX. J Urol 1999;161(4):329.
60. Maru N, Utsunomiya T, Bergamaschi F, **Kattan MW**, Scardino PT, Wheeler TM, Slawin KM. The influence of pathological parameters of positive surgical margins on prognosis in patients undergoing radical prostatectomy [Abstract]. 94th Annual Meeting of the American Urological Association, Dallas, TX. J Urol 1999;161(4):355.
61. Karakiewicz PI, **Kattan MW**, Scardino PT, Bazinet M, Elihilali MM, Tanguay S, Aprikian AG. The impact of comorbidity and socioeconomic status (SES) on utility scores following radical prostatectomy (RP) in the province of Quebec (PQ) [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):255.
62. Lee CT, Genega EM, Hutchinson B, Fearn PA, **Kattan MW**, Russo P, Reuter VE. Conventional (clear cell) renal carcinoma metastases have greater Bcl-2 expression than high risk primary tumors [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):473.
63. **Kattan MW**, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. A pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1158.
64. Karakiewicz PI, **Kattan MW**, Scardino PT, Bazinet M, Elihilali MM, Tanguay S, Aprikian AG. Longitudinal analysis of utility scores in men treated with radical prostatectomy (RP) in the province of Quebec (PQ) [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1270.

65. Ohori M, Suyama K, Maru N, Wheeler TM, **Kattan MW**, Scardino PT. Prognostic significance of systemic needle biopsy findings [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1275.
66. Rabbani F, Stapleton AM, Wheeler TM, **Kattan MW**, Scardino PT. Predicting recovery of erectile potency after radical prostatectomy: influence of age, preoperative potency, and extent of nerve-sparing [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1277.
67. Leventis AK, Shariat SF, **Kattan MW**, Wheeler TM, Slawin KM. Predictors of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1280.
68. Maru N, Utsunomiya T, **Kattan MW**, Scardino PT, Wheeler TM. Significance of perineural invasion in addition to other pathological features in the prediction of progression of prostate cancer [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1428.
69. Porter CR, Adler H, Rabbani F, **Kattan MW**, Gaudin P, Wheeler TM, Scardino PT. Significance of variations in the rate of positive surgical margins (+SM) in radical prostatectomy specimens (RPS) [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1432.
70. **Kattan MW**, Blasko JC, Beyer DC, Cavanagh W, Grimm P, Sylvester J, Fearn P, Potters L. A multi-institutional nomogram for predicting the outcome of ultrasound guided transperineal brachytherapy in prostate cancer [Abstract]. 95th Annual Meeting of the American Urological Association, Atlanta, Ga. J Urol 2000;163(4):1441.
71. Ross PT, Littenberg B, Fearn PA, Scardino PT, **Kattan MW**. A modified approach for measuring patient utilities for current health status [Abstract]. 22nd Annual Meeting of the Society for Medical Decision Making, Cincinnati, Oh. Med Decis Making 2000;20(4):494.
72. Karakiewicz PI, **Kattan MW**, Scardino PT, Mostafa ME, Tanguay S, Aprikian AG. Cross-cultural validation of the UCLA/Rand prostate cancer Index (PCI) [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):30.
73. Cagiannos I, Arons R, Graefen M, **Kattan MW**, Scardino PT, Karakiewicz PI. Low surgical volume is an independent predictor of prolonged hospital stay and higher cost of radical prostatectomy (RP) [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):30.
74. Cagiannos I, Karakiewicz P, Graefen M, Eastham J, Bochner B, Ohori M, Rabbani F, Gerigk C, Reuter V, Fair W, Scardino PT, **Kattan MW**, Wheeler M, Maru N, Schroeder FH, Wildhagen M, Stricker PD, Quinn DI, Lieskovsky G, Skinner DG, Kupelian P, Klein EA, Hammerer PG, Huland H. Year of radical prostatectomy is an independent predictor of outcome in prostate cancer. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):64.
75. Shariat S, Shalev M, Diaz-Meneses A, Kim IY, Wheeler TM, Slawin K, **Kattan MW**. Preoperative plasma levels of transforming growth factor  $\beta_1$  strongly predict progression in patients undergoing radical prostatectomy. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):203.

76. Shariat S, Lamb DJ, Nguyen C, Beck J, Kim J, Jang Y, Wheeler TM, Slawin K, **Kattan MW**. Preoperative plasma level of insulin-like growth factor binding protein-2 predicts progression in patients undergoing radical prostatectomy. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):204.
77. Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Bochner B, Ohori M, Rabbani F, Fair W, Scardino PT, **Kattan MW**, Lieskovsky G, Skinner DG, Hammerer PG, Huland H. Clinical stage T2 prostate cancer treated with radical prostatectomy has the same outcome across its substages. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):233.
78. Hwang YM, Ohori M, Kher S, **Kattan MW**, Scardino PT, Maru N, Muramoto M, Wheeler TM, Slawin K, Shariat S, Gore J. Improved prediction of extracapsular extension (ECE) using individually labeled systematic biopsies (SYSBX) in patients undergoing radical Prostatectomy (RP). [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):236.
79. Gore JL, Sahriat S, Ayala GE, Miles BJ, Kadmon D, Wheeler TM, Slawin K, **Kattan MW**. Individual laterally-directed biopsy cores predict the site of extracapsular extension in patients undergoing radical prostatectomy. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):237.
80. Cagiannos I, Graefen M, Eastham JA, Ohori M, Scardino PT, **Kattan MW**, Porter C, Genega E, Maru N, Wheeler TM, Hammerer PG, Erbesdobl A, Huland H. A pre-operative nomogram predicting positive surgical margins after radical prostatectomy. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):239.
81. Ohori M, Graefen M, Scardino PT, Hwang YM, Kher S, **Kattan MW**, Huland H, Hammerer PG, Maru N, Wheeler TM, Slawin K, Shariat S, Gore JL. Development of an improved nomogram including features of systematic biopsies to predict organ confined (OC) prostate cancer in Patients undergoing radical prostatectomy (RP). [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):240.
82. Karakiewicz PI, **Kattan MW**, Shariat S, Naderi A, Turner K, Slawin K, Kim ED. In men with localized prostate cancer (PCA) the international index of erectile function (IIEF) EF scale may be reduced to two items without loss in validity or reliability. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):273.
83. Graefen M, Karakiewicz PI, Scardino PT, **Kattan MW**, Haese A, Hammerer PG, Palisaar J, Huland E, Huland H. Percentage of free PSA (%FPSA) is not an independent predictor of pathologic stage or PSA recurrence in patients with localized prostate cancer treated with radical prostatectomy (RP). [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):281.
84. Shariat S, Gore JL, Gottenger E, Nguyen C, Song W, Andenoro J, Wheeler TM, **Kattan MW**, Slawin K. Preoperative RT-PCR assay for HK2 is associated with an increased risk of biochemical recurrence in patients undergoing radical prostatectomy. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):321.

85. **Kattan MW**, Fearn PA, Leibel S, Potters L, Kupelian PA. The definition of biochemical failure in patients treated with definitive radiotherapy. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):322.
86. Potters L, Torre T, **Kattan MW**, Fearn P, Leibel SA. The role of external radiotherapy and permanent prostate brachytherapy in low and intermediate risk patients with localized prostate cancer. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):324.
87. Karakiewicz PI, **Kattan MW**, Scardino PT, Elhilali MM, Aprikian AG. Assessment of the impact of surgical volume, hospital type and urologist's age on prostate cancer (PCA) specific health-related quality-of-life (HRQOL) detriments after radical prostatectomy (RP). [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):330.
88. Graefen M, Karakiewicz PI, **Kattan MW**, Rabbani F, Ohori M, Cagiannos I, Bochner B, Eastham JA, Fair W, Reuter V, Scardino PT, deKernion JB, Cangiano T, Lievskovsky G, Skinner DG, Kupelian P, Klein EA, Quinn DI, Striker PD, Huland H, Henke R, Hammerer PG, Schroeder FH, Wildhagen M, Wheeler TM. Cross-cultural assessment of predictors of disease recurrence after radical prostatectomy: a pooled analysis of 9256 cases. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):353.
89. Torre T, Potters L, Wang X, Calugaru E, **Kattan MW**, Fearn P. Biopsy location and biochemical relapse after permanent prostate brachytherapy. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):353.
90. Graefen M, Karakiewicz PI, Ohori M, **Kattan MW**, Haese A, Palisaar J, Scardino PT, Hammerer PG, Erbersdobler A, Henke R, Huland H. Percentage of Gleason pattern 4/5 in radical prostatectomy (RP) specimen is the strongest predictor of PSA failure after radical. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):354.
91. Ohori M, Graefen M, Hwang YM, **Kattan MW**, Scardino PT, Maru N, Wheeler TM, Slawin K, Shariat S, Gore JL, Hammerer PG, Huland H, Erbersdobler A. Features of cancer in systematic biopsies (SYSBX) improve the prediction of clinical indolent prostate cancer (PCA) in patients undergoing radical prostatectomy (RP). [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):354.
92. Potters L, Torre T, Leibel SA, Fearn P, **Kattan MW**. Potency following permanent prostate brachytherapy for localized prostate cancer. [Abstract]. 96th Annual Meeting of the American Urological Association, Anaheim, Ca. J Urol 2001;165(5):351.
93. **Kattan MW**, Karakiewicz PI, Shariat S, Slawin K. Test-retest reliability of a self-administered, paper-based standard gamble (Paper Gamble). [Abstract]. Med Decis Making 2001; 21(6): 525.
94. Klein EA, Kupelian P, **Kattan MW**, Graefen M, Cagiannos I, Eastham, JA, Scardino PT, Huland H. Age and PSA predict the likelihood of organ-confined disease in men presenting with psa < 10 ng/ml: implications for screening. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):70.

95. Bianco F, **Kattan MW**, Scardino PT, Powell J, Pontes EJ, Wood DP. Validation of Kattan preoperative and postoperative nomograms in african-american men with prostate cancer. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):103.
96. Yossepowitch O, Ohori M, Sircari K, **Kattan, MW**, Scardino PT, Wheeler TM, Reuter VE. Bladder neck involvement in radical prostatectomy specimens – is it appropriate to be staged as PT4? [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):225.
97. Karakiewicz PI, **Kattan, MW**, Karakiewicz PI, Eastham, JA, Ohori M, Rabbani F, Gerigk C, Reuter VE, Graefen M, Hammerer PG, Erbesdobler A, Huland H, Klein E, Kupelian P, Sutherland RL, Quinn D, Henshall S, Grygiel J, Stricker P, Scardino PT. A pre-operative nomogram identifying prostate cancer patients with increased risk of positive lymph nodes. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):230.
98. Graefen M, Karakiewicz PI, Palisaar J, Haese A, Hammerer PG, **Kattan, MW**, Scardino PT, Huland H. A comparison of two preoperative nomograms predicting recurrence following radical prostatectomy. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):231.
99. Eastham JA, **Kattan MW**, Gerigk C, Scardino PT. Surgeon is an independent risk factor for positive surgical margins (+ SM) at the time of radical prostatectomy (RP). [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):233.
100. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, **Kattan MW**. A survival nomogram for castrated patients with progressive metastatic prostate cancer. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):304.
101. Lopez-Corona E, Ohori M, Reuter VE, Gonen M, Scardino PT, **Kattan MW**. Which parameters predict a positive repeat prostate biopsy in patients suspected of having prostate cancer? [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):324.
102. Singh H, Shariat SF, Canto E, **Kattan MW**, Karakiewicz PI, Slawin K. Impact of interposition sural nerve graft on urinary control in patients undergoing radical prostatectomy. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):346.
103. Scardino PT, **Kattan MW**, Koh H, Eastham JA, Shariat SF, Raptidis G, Slawin K, Maramoto M, Wheeler TH. Peripheral zone and transition zone prostate cancers have a different prognosis. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):356.
104. **Kattan MW**, Zelefsky MJ, Scardino PT, Fuks Z, Leibel S. A nomogram which predicts 7-year metastasis-free survival following 3D conformal radiation therapy. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):355.
105. Perrotti M, Ankem M, Weiss RE, Epstein R, Decarvalho VS, **Kattan MW**, Cummings KB. Endorectal MRI: Adjunct to repeat biopsy in prostate cancer detection. The smart biopsy. [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. J Urol 2002;167(4):387.

106. Koh H, Suyama K, Maru N, **Kattan MW**, Muramoto M, Shariat SF, Slawin K, Scardino PT, Reuter VE, Wheeler TM, Ohori M. Does the largest cancer in radical prostatectomy (RP) specimens have the worst pathological features? [Abstract]. 97th Annual Meeting of the American Urological Association, Orlando, FL. *J Urol* 2002;167(4):354.
107. Littenberg B, Partilo S, Licata AL, **Kattan MW**. The reliability of a paper-based instrument to assess utility by standard gamble [Abstract]. Society of General Internal Medicine National Meeting, May 3, 2002. *J Gen Intern Med* 2002;17(Suppl 1):138.
108. Hu JC, Elkin EP, Pasta DJ, Lubeck DP, **Kattan MW**, Carroll PR, Litwin MS. Predictors of Quality Of Life Outcomes After Radical Prostatectomy: Results from Capsure. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003;169(4):15.
109. Dotan ZA, Cho D, Fearn P, Scardino PT, **Kattan MW**. Prognostic Factors for the Prediction of Metastasis Progression in Patients with Biochemical Recurrence Following Radical Prostatectomy. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4) No. 4:74.
110. Sadeghi F, Shariat S, **Kattan MW**, Andrews B, Wheeler TM, Slawin KM. Elevated Plasma Levels of Urokinase Plasminogen Activator and its Receptor are Strongly Associated with Prostate Cancer Presence and Progression. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4): 161.
111. Richstone L, Scherr DS, Snyder M, Sorbellini M, Rabbani F, **Kattan MW**, Russo P. Multifocal Renal Cell Carcinoma: Incidence, Risk Factors, and Survival. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):175.
112. Swindle P, Ohori M, **Kattan MW**, Wheeler T, Maru N, Slawin K, Eastham J, Scardino P. Do Margins Matter? The Prognostic Significance of Positive Surgical Margins in Radical Prostatectomy Specimens—18 Year Experience. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):180.
113. Ohori M, Koh H, Scardino PT, Maru N, Slawin KM, Shariat SF, Wheeler TM, Muramoto M, **Kattan MW**. A Nomogram for Predicting the Side-Specific Probability of Extracapsular Extension (ECE) in Radical Prostatectomy (RP) Specimens. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):292.
114. Swindle P, Sella T, Schwartz L, **Kattan MW**, Scher H, Hricak H, Scardino P. Clinical and Pathological Features of Patients with Proven Local Recurrence After Radical Prostatectomy as Detected by Endorectal Coil MRI. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):292.
115. Anwuri VA, Shariat SF, Lamb DJ, **Kattan MW**, Wheeler TM, Slawin KM. Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Marker-1 With Biochemical Progression After Radical Prostatectomy. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):386.
116. Lopez-Corona E, Ohori M, Reuter VE, **Kattan MW**, Scardino PT, Eastham J. Histologic Findings in the Initial Negative Prostate Biopsy and Risk of Subsequent Prostate Cancer Detection: The Current Predictive Value of High Grade Pin. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):424.

117. Ohori M, Wheeler TM, Maru N, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Eastham JA, Scardino PT, **Kattan MW**. Counseling Men With Prostate Cancer (PCA): A Nomogram for Predicting the Presence of Indolent (Small, Well-Moderately Differentiated, Confined) Tumors. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):425.
118. Grossfeld GD, Elkin EP, Pasta DJ, Lubeck DP, **Kattan MW**, Mehta SS, Carroll PR. Validation of the Kattan Pre-Treatment Nomogram in Community Patients Undergoing Radical Prostatectomy: Results from Capsure. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):444.
119. Ishii J, Ohori M, **Kattan MW**, Scardino PT, Tsuboi T, Slawin KM, Wheeler TM. Significance of the Craniocaudal Distribution of Cancer in Radical Prostatectomy (RP) Specimens. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):455.
120. DiBlasio CJ, Fearn P, Seo HS, **Kattan MW**, Scardino PT. Association Between Number of Lymph Nodes Removed and Freedom from Disease Progression in Patients Receiving Pelvic Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):456.
121. Gorbonos A, Ohori M, Maru N, **Kattan MW**, Wheeler TM, Slawin KM, Scardino PT. Prognostic Significance of the Site of the Positive Margin (+SM) in Radical Prostatectomy (RP) Specimens. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):457.
122. **Kattan MW**, Wilson TH, Roehrborn C, Slawin K. Development of a Nomogram to Predict BPH Progression With or Without Dutasteride Therapy. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):475.
123. Tsuboi T, Ohori M, Reuter VE, **Kattan MW**, Eastham JA, Scardino PT. Are Intraoperative Frozen Sections an Efficient Way to Reduce Positive Surgical Margins? [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):492.
124. Potters L, **Kattan MW**, Huang D, Fearn P, Calugaru E, Leibel S. The Importance of Implant Quality for Patients Undergoing Prostate Brachytherapy. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):493.
125. Russo P, Snyder ME, DiBlasio CJ, Sorbellini M, **Kattan MW**, Motzer RJ, Reuter VE. Changing Demographics and the Contemporary Surgical Management of Renal Cortical Tumors. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):347.
126. Sorbellini M, **Kattan MW**, Snyder M, Russo P. A Novel Postoperative Prognostic Nomogram for Conventional Clear-Cell Renal Cell Carcinoma. [Abstract]. 98th Annual Meeting of the American Urological Association, Chicago, IL. *J Urol* 2003; 169 (4):348.
127. **Kattan MW**, Mazumdar M, Brennan MF, Karpel MS. Postoperative nomogram for disease-specific survival following an R0 resection for gastric carcinoma. *Proc Am Soc Clin Oncol* 22: page 293, 2003 (abstr 1177).

128. Halabi S, Small E, **Kattan M**, Kantoff P, Dawson N, Levine E, Oh W, Kaplan E, Vogelzang N. A model for predicting progression free survival in men with hormone refractory prostate cancer (HRPC): An analysis of CALGB studies. *Proc Am Soc Clin Oncol* 22: page 397, 2003 (abstr 1597)
129. **Kattan M**, Giri D, Hummer A, Panageas M, Cranor M, Vanzee K, Borgen PI, Hudis C, Norton L, Tan L. A nomogram predicting 15 year breast cancer survival in women with negative axillary lymph nodes (ALNS) by routine histopathologic analysis and without adjuvant therapy. *Proc Am Soc Clin Oncol* 22: page 872, 2003 (abstr 3505).
130. Stephenson AJ, Shariat SF, **Kattan MW**, Zelefsky MJ, Butler EB, Kupelian PA, Klein EA, Scardino PT, Leibel SA, Slawin KM. Predicting the outcome of salvage radiotherapy for suspected local recurrence of prostate cancer after radical prostatectomy. *Proc Am Soc Clin Oncol* 22: page 392, 2003 (abstr 1577).
131. **Kattan MW**, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival following an R0 resection for gastric carcinoma [Abstract] *Med Decis Making* 23(6): page 553, 2003.
132. **Kattan MW**, Gonen M, Feye J, Van Zee KJ. Clinicians versus statistical model for predicting a breast cancer patient's lymph node status [Abstract]. *Med Decis Making* 23(6): page 554, 2003.
133. **Kattan MW**, Elkin E, Steffel M, and Cowen ME. The method of utility assessment affects decision analytic recommendations: a prostate cancer treatment example [Abstract]. *Med Decis Making* 23(6): page 561, 2003.
134. **Kattan MW**, Giri D, Panageas KS, Hummer A, Cranor M, Van Zee KJ, Hudis CA, Norton L, Borgen PI, Tan LK. A tool for predicting 15-year breast cancer death in women who do not receive adjuvant therapy [Abstract]. *Med Decis Making* 23(6): page 565, 2003.
135. Bianco FJ, Dotan ZA, **Kattan MW**, Fearn PA, Eastham JA and Scardino PT. Clinical course and response to first-line androgen deprivation therapy in patients with PSA-progression after radical prostatectomy [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. *J Urol* 2004; 171(4):116.
136. Stephenson AJ, Singh H, Canto EI, Shariat SF, **Kattan MW**, Scardino PT, Kadmon D, Miles BJ, Wheeler TM, and Slawin KM. Predictors of prostate cancer detection using an extended biopsy regimen in patients with a total PSA between 2.5 and 4.0 ng/ml [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. *J Urol* 2004; 171(4):170.
137. Stephenson AJ, Di Blasio CJ, Eastham JA, Scardino PT, and **Kattan MW**. Predicting the 10-year probability of prostate cancer recurrence: an updated postoperative nomogram and a suite of nomograms for patients who are free of disease at one to five years after radical prostatectomy [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. *J Urol* 2004; 171(4):208.
138. Stephenson AJ, Smith A, Satagopan J, **Kattan MW**, Reuter VE, Scardino PT, and Gerald WL. Microarray-based nomogram for disease recurrence after radical prostatectomy: combining gene expression information with clinical variables to enhance predictive accuracy [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. *J Urol* 2004; 171(4):209.

139. Bianco FJ, Scardino PT, **Kattan MW**, Rhee AC, and Eastham JA. Surgeon volume is predictor of improved outcomes in radical prostatectomy patients [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):211.
140. Di Blasio CJ, Rhee AC, Scardino PT, **Kattan MW**. The association between body mass index (BMI) and disease progression in clinically localized prostate cancer. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):211.
141. Ishii J, Ohori M, **Kattan MW**, Scardino PT, Tsuboi T, Slawin KM, Wheeler TM. Presence of peripheral zone cancer at the apical shave is important prognostic factor. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):212.
142. Saranchuk J, Touijer AK, **Kattan MW**, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):212.
143. Dotan ZA, Bianco FJ, Fearn PA, Chen H, Eastham JA, Rabbani F, Eberhardt SC, Hricak H, Scardino PT, **Kattan MW**. Bone scan in assessing biochemical failure after radical prostatectomy—efficacy and risk factors for a positive bone scan. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):225.
144. Richstone L, Shah HH, Chen H, **Kattan MW**, Schlegel PN, Vaughan ED, Eastham JA, Scardino PT, Scherr DS. Radical prostatectomy (RRP) in men >70 years old: effect of age on upgrading, upstaging and accuracy of preoperative nomograms. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):226.
145. **Kattan MW**, Eastham JA, and Scardino PT. A pretreatment nomogram for predicting the need for additional therapy following radical prostatectomy for prostate cancer. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):226.
146. Mullerad M, Adusumilli PS, Kikuchi E, Bochner BH, **Kattan MW**, Chou T, Fong Y. Herpes simplex virus-based gene therapy enhances the efficacy of mitomycin-c in the treatment of human bladder transitional cell carcinoma. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):259.
147. Saranchuk JW, Touijer AK, Chen H, **Kattan MW**, Scardino PT. Is radical prostatectomy performed by trainees associated with a worse outcome? [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):273.
148. Bianco FJ, Dotan ZA, **Kattan MW**, Fearn PA, Eastham JA, and Scardino PT. 15-year cancer-specific and PSA-progression free rates after radical prostatectomy. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):313.
149. Stephenson AJ, Shariat SF, Zelefsky MJ, **Kattan MW**, Roehrborn CG, Pistenmaa DA, Klein EA, Kupelian PA, Butler EB, Leibel SA, Scardino PT and Slawin KM. Defining the characteristics of locally recurrent prostate cancer after radical prostatectomy based on the results of salvage radiotherapy: a multi-center analysis. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):382.

150. Cho D, Di Blasio CJ, Snyder ME, Dotan ZA, **Kattan MW**, and Russo P. Contemporary surgical management of renal cortical tumors of 7cm or less. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):471.
151. Schachter LR, Bach AM, Snyder ME, **Kattan MW**, and Russo P. The impact of tumor location on histologic subtype of renal cortical tumors. [Abstract]. 99<sup>th</sup> Annual Meeting of the American Urological Association, San Francisco, CA. J Urol 2004; 171(4):172.
152. Elkin EB, Saranchuk JW, Touijer Ak, Scardino PT, Eastham JA, **Kattan MW**. Achieving optimal outcomes after radical prostatectomy: Assessing postoperative trajectory using a Markov model. [Abstract]. 26<sup>th</sup> Annual Meeting of the Society for Medical Decision Making. Atlanta, Georgia, October 2004.
153. Sorbellini M, **Kattan MW**, Snyder ME, Hakimi AA, Berger DM, Russo P. Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. J Urol 2005; 173(4):13
154. Bianco FJ, Reidel ER, Begg CB, **Kattan MW**, Scardino PT. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. J. Urol 2005; 173(4):51-52.
155. Stephenson AJ, Scardino PT, Eastham JA, Lilja H, Bianco FJ, Dotan, ZA, **Kattan MW**. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. J Urol 2005; 173(4): 183.
156. Scardino PT, Fearn PA, Stephenson AJ, Dotan ZA, Steuber T, Graefen M, Huland H, Eastman JA, **Kattan MW**. Prediction and natural history of organ confined prostate cancer after RP. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. J Urol 2005;173(4):271
157. Bianco FJ, Dotan ZA, **Kattan MW**, Stephenson AJ, Scher HI, Fearn PA, Eastham JA, Scardino PT. Natural History of biochemically-recurrent castrate-resistant disease in men treated with maximal androgen blockage for a rising PSA after radical prostatectomy. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. J Urol 2005;173(4):309.
158. Isom-Batz G, Bianco FJ, **Kattan MW**, Mulhall JP, Eastham JA. Testosterone as a predictor of pathologic stage in clinically localized prostate cancer. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. J Urol 2005;173(4):384.
159. Steuber T, **Kattan MW**, Piironen T, Haese A, Huland H, Brunner N, Danø K, Høyer-Hansen G, Lilja H. Measurement of urokinase receptor fractions and human glandular kallikrein 2 in serum improves discrimination of men with prostate cancer from men with no evidence of malignant disease. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. J Urol 2005;173(4):404.

160. Slawin KM, Roehrborn CG, McConnell JD, Kreder KJ, Jacobs SC, McVary KT, Foster HE, Clarke HS, Milan DF, Noble WD, Nybert LM, Kusek JW, **Kattan MW**. Development of a nomogram to predict symptom progression with or without medical therapy in men with BPH based on data from the MTOPS trial. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. *J Urol* 2005;173(4):444.
161. Slawin KMN, McDonnell JD, Roehrborn CG, Kaplan SA, Smith JA, Lepor H, Diokno AC, Noble WD, Nyberg LM, Kusek JW, **Kattan MW**. Development of a nomogram to predict acute urinary retention of BPH-related surgery with or without medical therapy in men with BPH based on data from the MTOPS Trial. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. *J Urol* 2005;173(4):444.
162. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, **Kattan MW**. Predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy: a new preoperative nomogram. [Abstract] 2005 Annual Meeting of the American Urological Association, San Antonio, TX. *J Urol* 2005;173(4):450.
163. **Kattan MW**, Cuzick J, Scardino PT, Transatlantic Prostate Group. Natural History of prostate cancer in a large cohort of untreated patients in the United Kingdom. [Abstract] 2005 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2005 23(16S): Abstract No. 4512:381s.
164. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, **Kattan MW**. Pretreatment nomogram predicting the long-term risk of metastatic progression of prostate cancer after radical prostatectomy. [Abstract] 2005 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2005 23(16S): Abstract No. 4545:389s.
165. Bianco FJ, **Kattan MW**, Beekman KW, Scher HI, Scardino PT. Prognosis after androgen deprivation therapy in men with a rising PSA after prostatectomy. [Abstract] 2005 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2005 23(16S): Abstract No. 4552:390s.
166. Sekeres MA, Jin T, Maciejewski J, Kalaycio ME, Brown S, Advani A, Golshayan A, Sobecks R, **Kattan MW**. Characterization, resource use, and the economic impact of low-risk myelodysplastic syndrome (MDS) at an MDS specialty center. [Abstract] 2005 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2005 23(16S): Abstract No. 6098:552s.
167. Agus DB, Sweeney CJ, Morris M, Mendelson D, McNeel DG, Ahmann F, Wang J, Derynck MK, **Kattan MW**, Scher HI. Efficacy and safety of single agent pertuzumab (rhuMAb 2C4) a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy. [Abstract] 2005 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2005 23(16S): Abstract No. 4624:408s.
168. Snyder ME, Bach E, **Kattan MW**, Raj GV, Reuter VE, Russo P. Incidence of benign lesions for clinically localized renal masses <7cm in radiologic diameter: influence of gender. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. *J Urol* 2006 April;175(4):29.
169. Bird ET, Ritter R, Coffield KS, Rampisela D, Speights VO, **Kattan MW**. Validation of a nomogram for predicting a repeat positive prostate biopsy in a rural/nonurban setting. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. *J Urol* 2006 April;175(4):64.

170. Bennett CL, Sartor O, Halabi S, **Kattan MW**, Scardino PT. Variations in prostate cancer care according to race, geographic region, and literacy: initial findings from the COMPARE registry. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):66.
171. Bianco FJ, **Kattan MW**, Eastham JA, Guillonneau B, Scardino PT, Mulhall JP. Role of surgeon and surgeon volume in erectile function recovery after radical prostatectomy. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):70.
172. Artibani W, Cosciani-Cunico S, Anselmo G, Zattnoi F, **Kattan MW**. Nomogram predictive of cancer-specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):148.
173. Bianco FJ, Yossepowitch O, Eastham JA, Dotan ZA, Stephenson AJ, **Kattan MW**, Scardino PT. Studies on rising PSA after RP: trends on secondary treatments. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):159.
174. Ficarra V, Artibani W, Cosciani-Cunico S, Anselmo G, Zattoni F, **Kattan MW**. Nomogram predictive of pathological inguinal lymph node involvement in patients with squamous cell carcinoma of the penis. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):194.
175. Stephenson AJ, Eastham JA, **Kattan MW**, Bianco FJ, Dotan ZA, Scardino PT. Long-term risk of metastatic progression of prostate cancer following radical prostatectomy. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):210.
176. Baccala AA, Reuther AM, Bianco FJ, Scardino PT, Klein EA, **Kattan MW**. A postoperative nomogram for detecting 13-year probability of disease recurrence from prostate cancer. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):213.
177. Bianco FJ, Scardino PT, Scher HI, Stephenson AJ, Dotan ZA, Eastham JA, **Kattan MW**. Studies on androgen deprivation therapy for a rising PSA prostatectomy: development of castrate metastasis (hormonally refractory prostate cancer). [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):383.
178. Stephenson AJ, Pollack A, Scardino PT, **Kattan MW**, Pisansky TM, Slawin KM, Klein EA, Kupelian PA, Anscher MS, Michaelski JM, Sandler HM, Zelefsky MJ, Forman JD, Lin DW, Kestin LL, Pistenmaa DA, Catton CN, Dewese TL, Valicenti RK, Kuban DA, Bianco FJ, Fearn PA. A nomogram to predict the outcome of salvage radiotherapy (RT) for biochemical recurrence (BCR) following radical prostatectomy (RP). [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):384.
179. Slawin KM, Levitt JM, Lamb DJ, Murthy L, Chuang W, Lu HK, **Kattan MW**. Baseline serum BPH-A level enhances the accuracy of a nomogram to predict BPH progression in men enrolled on the GSK phase III dutasteride trials. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. J Urol 2006 April;175(4):436.

180. Slawin KM, Levitt JM, Lamb DJ, Murthy L, Chuang W, Lu HK, **Kattan MW**. Prediction of prostate volume using molecular forms of PSA in men with BPH enrolled on the GSK phase III dutasteride trials. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. *J Urol* 2006 April;175(4):439.
181. Roobol MJ, Steyerberg EW, **Kattan MW**, De Konig HJ, Schröder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. *J Urol* 2006 April;175(4):449.
182. Kibel AS, **Kattan MW**, Picus J, Dreicer R, Klein EA, Wilding G, Jarrard DF, Roth B, Cookson MS, Petrylak DP, Chatta G, Nelson JB, Beer TM, Dipaola R, Partin AW, Rosenbaum E, Garrett E, Sugar E, Eisenberger M. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. *J Urol* 2006 April;175(4):512.
183. Ngan C, **Kattan MW**, Moussa M, Jevnikar AM, Gill J, Karnik V, Miller T, Rouse T, Gotto G, Randhawa P, Luke P. Development of a nomogram for the assessment of cadaveric donor kidneys for transplantation. [Abstract] American Urological Association Annual Meeting, Atlanta, GA. *J Urol* 2006 April;175(4):542.
184. Stephenson AJ, Pollack A, **Kattan MW**, Scardino PT. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. [Abstract] 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA. *J Clin Oncol* 2006 24(18S): Abstract No. 4514.
185. Dotan ZA, Sathymoorthy K, Bianco Jr FJ, Stephenson AJ, Eastham JA, Fearn P, Schöder H, Scher HI, Scardino PT, **Kattan MW**. The probability of a positive bone scan in patients who were treated with androgen ablation therapy for rising PSA after radical prostatectomy. [Abstract] 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA. *J Clin Oncol* 2006 24(18S). Abstract No. 4574.
186. Sartor O, Bennett CL, Halabi S, **Kattan MW**, Scardino PT. Race/ethnicity, literacy and prostate cancer: initial findings from the COMPARE registry. [Abstract] 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA. *J Clin Oncol* 2006 24(18S). Abstract No. 4620.
187. Chi DS, Sonoda Y, Abu-Rustum NR, Awtrey CS, Huh J, Barakat RR, **Kattan MW**. Nomogram for survival after primary surgery for bulky stage IIIc ovarian carcinoma. [Abstract] 2006 Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA. *J Clin Oncol* 2006 24(18S). Abstract No. 5058.
188. Heath EI, **Kattan MW**, Powell IJ, Sakr W, Brand T, Rybicki B, Thompson IM, Aronson WJ, Terris M, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ. Are the partin tables accurate for African-american men in the United States? [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 328.
189. Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR Jr, Frank I, Permpongkosol S, Weight CJ, **Kattan MW**, Novick AC. Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 495.

190. Vickers AJ, Serio AM, Eastham JA, Scardino PT, Klein EA, Reuther AM, **Kattan MW**, Pontes JE. Variations among experienced surgeons and cancer control rates after radical prostatectomy. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 616.
191. Mulhall JP, Bennett NE Jr, Eastham JA, Scardino PT, **Kattan MW**. Development of pre and post-operative nomograms for erectile function recovery after radical prostatectomy. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 855.
192. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, **Kattan MW**. Pre-surgical nomogram predicting 12-year probability of metastatic recurrence following nephrectomy for renal masses. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 1250.
193. Vickers AJ, Bianco FJ Jr, Serio AM, Eastham JA, Schrag D, Gonen M, Klein EA, Reuther AM, **Kattan MW**, Pontes JE, Scardino PT. Effects of patient risk on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 1398.
194. Lane BR, Stephenson AJ, Reuther AM, **Kattan MW**, Magi-Galluzzi C, Zhou M, Lakin MM, Klein EA. Low pretreatment total testosterone levels are associated with predominance of pattern 4 prostate cancer at prostatectomy and risk of biochemical recurrence. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 1617.
195. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, **Kattan MW**, Stock RG. Multicenter analysis of outcomes in patients treated with permanent prostate brachytherapy: effect of PSA failure definition and dose on biochemical defined relapse. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 1763.
196. Goldfarb DA, **Kattan MW**, Alster JM, Thuita L, Poggio ED. Nomograms to predict graft function and survival in living donor kidney transplantation. [Abstract] 2007 Annual Meeting of the American Society of Clinical Oncology, Anaheim, CA. *J Clin Oncol* 2007 177(4S). Abstract No. 1898.
197. Nguyen CT, Fu ZA, Gilligan TD, **Kattan MW**, Wells BJ, Klein E. Decision analysis model for clinical state 1 non-seminomatous germ cell testicular cancer. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:174.
198. Thompson RH, Raj GV, Leibovich BC, Russo P, Blute ML, **Kattan MW**. Preoperative nomogram to predict positive lymph nodes during nephrectomy for renal cell carcinoma. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:212.
199. Vickers AJ, Cronin AM, **Kattan MW**, Gonen M, Milowsky MI, Scardino PT. Clinical benefits of a multivariable prediction model for bladder cancer: a decision analytic approach. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:320.

200. Bianco FJ, **Kattan MW**, Scardino PT. Predicting risk of prostate cancer-specific mortality based on clinicopathologic features at radical prostatectomy. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:553.
201. Fenig DM, **Kattan MW**, Mills JN, Ginsberg M, Lipshultz LI. Nomogram to preoperatively predict the probability of epididymovasostomy. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:593.
202. Rosoff JS, Tanrikut C, Goldstein M, Chu DI, **Kattan MW**, Mulhall J. Prognostic nomogram for the estimation of serum testosterone level following varicocele ligation. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:598.
203. Derweesh IH, Patterson AL, Wake RW, **Kattan MW**. Nomogram to predict prostate cancer diagnosis on transrectal ultrasound-guided biopsy in a contemporary series. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:643-644.
204. Stephenson AJ, Pollack A, **Kattan MW**, Scardino PT. Adjuvant radiation therapy for pathologically advanced prostate cancer after radical prostatectomy: a multi-institutional analysis. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:646.
205. Stephenson AJ, **Kattan MW**, Eastham JA, Klein EA, Bianco FJ. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen ERA. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:649.
206. Nam RK, Klotz LH, Trachtenberg J, **Kattan MW**, Narod SA. Clinical application of chromosome 8q24 SNPs in prostate cancer diagnosis. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:686.
207. Vickers AJ, Bianco FJ, Savage CJ, Klein EA, **Kattan MW**, Pontes JE. Surgery as a confounder of biology: the predictive value of stage, grade and prostate-specific antigen (PSA) for recurrence is a function of surgeon experience. [Abstract] American Urological Association Annual Meeting, Chicago, IL. *J Urol* 2008 April;179(4) Supplement:723.
208. Eisenberger MA, **Kattan MW**, Kibel A, Sternberg CN, Epstein J. Impact of central pathology review (CPR) of radical prostatectomy (RP) specimens for patient selection in the surgical adjuvant trial in prostate cancer (PCa) TAX-3501. [Abstract] 2008 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. *J Clin Oncol* 2008 May 20 Suppl; abstr 5128
209. Donahue TR, **Kattan MW**, Nelson SD, Tap WD, Eilber FC. Impact of neoadjuvant therapy on histopathologic response and survival in patients with primary high-grade retroperitoneal soft tissue sarcomas. [Abstract] 2008 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. *J Clin Oncol* 2008 May 20 Suppl; abstr 10510.
210. Talantov D, Jatko M, Bohm M, Zhang Y, Stricker P, **Kattan MW**, Sutherland RL, Kench JG, Wang Y, Henshall S. Gene-based prediction of PSA recurrence for clinically localized prostate cancer patients. [Abstract] 2009 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2009 May;27(15S):5132.

211. Stephenson AJ, Klein EA, **Kattan MW**, Han M, Partin AW, Walsh PC, Trock BJ, Wood DP, Eggener SE, Eastham JA, Scardino PT. Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. [Abstract] 2009 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2009 May;27(15S):5007.
212. Chi D, Zivanovic O, Kolev V, Yu C, Levine A, Sonoda Y, Abu-Rustum NR, Huh J, Barakat RR, **Kattan MW**. Nomogram for predicting 5-year survival after primary surgery for epithelial ovarian cancer. [Abstract] 2009 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. *J Clin Oncol* 2009 May;27(15S):5523.
213. Schroeck FR, **Kattan MW**, Moul JW, Aaronson WJ, Presti, Jr JC, Terris MK, Kane CJ, Armling CL, Sun L, Freedland SJ. Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. [Abstract] *J Urol* 2009 April 26:181(4) Supplement: 54.
214. Nguyen CT, Hernandez AV, **Kattan MW**, Stephenson AJ, Jones JS, Klein EA. Comparison of risk stratification models and the Kattan preoperative nomogram in prediction of freedom from PSA relapse after radical prostatectomy. [Abstract] *J Urol* 2009 April 26:181(4) Supplement: 469.
215. Larson BT, Campbel SC, Weight CJ, **Kattan MW**, Lane BR. Validation of a preoperative nomogram for solid enhancing renal tumors. [Abstract] *J Urol* 2009 April 26:181(4) Supplement: 216.
216. Margulis V, **Kattan MW**, Matin SF, Tamboli P, Janasch E, Tannir NM, Swanson DA, Wood CG. Prognostic nomograms for prediction of survival before or after cytoreductive nephrectomy for metastatic renal cell carcinoma. [Abstract] *J Urol* 2009 April 26:181(4) Supplement: 499-450.
217. Moussa AS, Gaurang S, Luay S, Yu C, **Kattan MW**, Jones JS. The perception of family history risk and its estimate role in having prostate cancer in the contemporary era. [Abstract] *J Urol* 2009 April 26:181(4) Supplement: 747-748.
218. Moussa AS, Jones JS, Yu C, Fareed K, Zippe CD, **Kattan MW**. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extending prostate sampling. [Abstract] *J Urol* 2009 April 26:181(4) Supplement: 749-750.
219. Moussa AS, Klein EA, Gong G, Yu C, **Kattan MW**, Jones SJ. A nomogram for predicting significance upgrading in patients with low and intermediate grade prostate cancer in the era of extending prostate sampling. [Abstract] *J Urol* 2009 April 26:181(4) Supplement: 472.
220. Stephenson A, Klein E, Ciezki J, Chandana R, **Kattan MW**, Yu C, Deasy J, Michalski J, Kallogjeri D, Lubahn J, Luly J, Piccirillo J, Kibel A. Overall and cancer specific survival following definitive therapy for clinically localized prostate cancer in the prostate-specific antigen era. [Abstract] *J Urol* 2010 April:183(4):e113.
221. Grubb RL, Black A, Shaul S, Mabie J, Riley T, **Kattan MW**, Ismirlian G, Vickers AJ, Bochner BH, Kibel AS, Prorok PC, Berg CD, Stephenson A, Andriole GL. Predicting the risk of bladder cancer using patient clinical and demographic information from PLCO participants. [Abstract] *J Urol* 2010 April:183(4):e448-e449.

222. Lee M, Moussa A, Yu C, **Kattan MW**, Jones JS. Initial diagnosis of high-grade prostatic intraepithelial neoplasia is a risk factor for subsequent development of prostate cancer. [Abstract] J Urol 2010 April;183(4):e770.
223. Vickers A, Bianco F, Cronin A, Eastham J, Klein E, **Kattan MW**, Scardino P. The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. [Abstract] J Urol 2010 April;183(4): 1360-1365.
224. Stephenson AJ, Eggener SE, Klein EA, Hernandez AV, **Kattan MW**, Wood DP, Eastham JA, Scardino PT. 470: Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. [Abstract] J Urol 2011;185(4) Supplement:e191.
225. Abd El-Latif A, Stephenson AJ, Klein EA, Hernandez AV, **Kattan MW**, Eggener SE, Wood DP, Eastham JA, Scardino PT. 474: Association of the number of lymph nodes (LN) removed at radical prostatectomy with all cause (ACM) and prostate cancer-specific mortality (PCSM). [Abstract] J Urol 2011;185(4) Supplement:e193.

#### **Peer-Reviewed Conference Proceedings:**

1. Glorfeld LW, **Kattan MW**. A comparison of the performance of three classification procedures when applied to contaminated data. Proc Dec Sci Instit, 1989.
2. Nelson RR, **Kattan MW**, Cheney PH. An empirical reexamination of the relationship among training ability and acceptance of information technology. Proc 1991 ACM SIGCPR Conf Manag Inf Sys Pers, Athens, Georgia, April 8-9, 1991.
3. **Kattan MW**, Adams DA. Explaining information technology use with the usefulness scale: A Comparison with user age. Proc 18th Annu Sympos Comp Applic Med Care, Washington, DC, 1994;81-85.
4. **Kattan MW**, Fearn PA, Cantor SB, Hu J, Cowen ME, Giesler RB, Miles BJ. Telephone interviews vs. workstation sessions for acquiring quality of life data. Proc Am Med Inf Ass Symp, 1999;296-300.
5. Demsar J, Zupan B, **Kattan MW**, Beck JR, Bratko I. Naïve Bayesian-based nomogram for prediction of prostate cancer recurrence. Stud Health Technol Inform 1999; 68:436-41.
6. Zupan B, Demsar J, **Kattan MW**, Beck JR, Bratko I. Machine learning for survival analysis: A case study on recurrence of prostate cancer. Artificial Intelligence in Medicine, 2000; 20 (1):59-76.
7. Zupan B, Demsar J, **Kattan MW**, Ohori M, Graefen M, Bohanec M, Beck JR. Orange and decisions-at-hand: bridging predictive data mining and decision support. IDAMAP 2001;151-162.
8. Demsar J, Zupan B, **Kattan MW**, Aoki N, Ohori, M. Graefen M, Beck RJ. Orange and decisions-at-hand: bridging medical data mining and decision support. Intelligent data analysis in medicine and pharmacology: IDAMAP 2001; 87-92.
9. **Kattan MW**, Fearn PA, Miles BJ. Time trade-off utility modified to accommodate degenerative and life-threatening conditions. Proc Am Med Inf Ass Symp, 2001; 304-308.

10. Fearn P, Scardino PT, **Kattan MW**. Towards an efficient chronological database to support medical statistical prediction. Proceedings of the Hawaii International Conference on Statistics and Related Fields. 2002.
11. Fearn PA, Regan K, Sculli F, Katz J, **Kattan MW**. A chronological database as backbone for clinical practice and research data management. Proceedings of the Sixteenth Annual IEEE Symposium on Computer-Based Medical Systems, New York, NY, 2003; 9-15.
12. Mozina M, Demsar J, **Kattan MW**, and Zupan B. Nomograms for visualization of naive bayesian classifier. 15th European Conference on Machine Learning and 8th European Conference on Principles and Practice of Knowledge Discovery in Databases, Pisa, Italy, September 20-24, 2004.
13. Fearn PA, Lafferty HJ, Bauer MJ, **Kattan MW**. A clinical research database solution for HIPAA privacy and security requirements. Medinfo. 2004:2004(CD):1588.

#### Letters:

1. Miles BJ, Cowen ME, **Kattan MW**, Giesler RB. Response to screening for prostate cancer [Letter]. JAMA 1995;273(15):1173-74.
2. Cowen ME, **Kattan MW**, Miles BJ. Response to survival for prostate cancer [Letter]. JAMA 1996; 275(1):31.
3. **Kattan MW**, Beck JR. In response – Cost-effectiveness of interferon as maintenance therapy in chronic myelogenous leukemia [Letter]. Ann Intern Med 1997;126(8):664-665.
4. **Kattan MW**, Cowen ME, Miles BJ. In response – A decision analysis for treatment of clinically localized prostate cancer [Letter]. J Gen Intern Med 1997;12(10): 659.
5. Cantor SB, **Kattan MW**. In response – Determining the area under the ROC curve for a binary diagnostic test [Letter]. Med Decis Making. 2001;21(5):422.
6. Cantor SB, **Kattan MW**. In response –Reply to Jager. [Letter] Med Decis Making. 2001;21(6):514.
7. Bianco FJ Jr, **Kattan MW**, Scardino PT. PSA velocity and prostate cancer. [Letter] N Engl J Med 2004 Oct 21;351(17): 1800-2.
8. Sadeghi S, Barzi A, **Kattan MW**, Meropol NJ. Screening for lynch syndrome in the general population [Letter]. Cancer Prev Res (Phila). 2011 Mar;4(3):471.